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Tuberculosis (TB) remains the infectious disease causing the greatest global mortality, 
with an estimated 10 million incident cases of TB and 1.45 million deaths in 2018. 
Although there is a cure for TB, the success of the treatment is hampered by multidrug 
resistant TB and HIV infection. There is an urgent need for an effective TB vaccine to 
prevent ongoing transmission. The development of a new and efficacious TB vaccine 
will likely be dependent on our understanding of protective immunity to TB. Although 
it is well established that Th1 cells are crucial in the response against Mycobacterium 
tuberculosis (Mtb), Th1 cytokines may not be sufficient to control Mtb infection. A 
major focus of this thesis is the contribution of an understudied Th subset in Mtb 
immunity, namely Th22 cells, producing the cytokine IL-22. IL-22 functions to 
preserve mucosal barriers and induce antimicrobial peptides, contributing to protective 
immunity to a range of extracellular and intracellular bacteria. A recent study in IL-22-
deficient mice described a protective role for IL-22 during the development of TB. In 
humans, soluble IL-22 has been detected at sites of extra-pulmonary tuberculosis (TB), 
and a polymorphism in the IL-22 promoter has been linked to TB susceptibility. 
However, much remains to be understood about Th22 cells and their role in protective 
immunity to Mtb. 
  
In this study, we investigated the contribution of Th22 cells to TB immune responses 
by providing a detailed characterisation of Mycobacterium tuberculosis-specific Th22 
cells in latent TB infection (LTBI), TB disease and HIV co-infection, using flow 
 iv 
cytometric techniques. In Chapter 2, we optimised detection of IL-22 and determined 
the factors that contribute to Mtb-specific IL-22 production by CD4+ T cells, as well as 
characterising some aspects of Th22 cell biology. In Chapter 3, we examined the impact 
of TB disease and HIV infection on Th22 cells, compared to Th1 and Th17 cells. 
Finally, in Chapter 4, we explored Mtb-specific cytokine production by CD8+ T cells 
and CD4+ T cells following Mtb peptide stimulation, and the effect of TB disease and 
HIV infection. 
 
We detected significant IL-22 production from CD4+ T cells in healthy individuals 
following whole blood stimulation with Mtb whole cell lysate (MtbL). However, IL-22 
responses were poorly detectable when peripheral blood mononuclear cells (PBMC) 
were stimulated with MtbL. Therefore, we sought to investigate conditions that 
influence IL-22 detection in whole blood and PBMC, and characterise Th22 cells 
further. We found that PBMC are able to produce IL-22 in response to Mtb but appear 
to lack the physiological environment for optimal induction of IL-22. We also 
discovered that TCR blocking inhibited Mtb-specific IL-22 production, suggesting that 
responses are stimulated through recognition of Mtb antigen by the TCR, rather than 
through bystander activation. IL-22 is produced by CD4+ T cells that appear to be 
conventional, rather than MAIT,   or iNKT cells. Indeed, analysis of the TCR 
clonality using v repertoire typing revealed similar repertoire usage between IL-22, 
IFN--producing CD4+ T cells, and total CD4+ T cells. Overall, these data shed more 
light on the biology of IL-22-producing CD4+ T cells. 
 
 v 
Next, we examined the effects of HIV infection and TB disease on the magnitude, 
memory profile and activation phenotype of Mtb-specific Th22 cells, compared them 
to Th1 and Th17 cells. Blood samples were collected from 72 individuals classified into 
four groups based on their HIV-1 and TB status, namely HIV-/LTBI, HIV+/LTBI HIV-
/active TB and HIV+/active TB. Blood was stimulated with MtbL and analysed for 
cytokine production using multiparameter flow cytometry. We observed similar 
frequencies of IL-22 to IFN--producing CD4+ T cells in LTBI. Mtb-specific Th22 
cells were reduced to a greater extent than Th1 cells by a combination of HIV infection 
and TB disease. Th22 cells demonstrated differences in their memory and activation 
phenotype compared to Th1 and Th17 cells. In the context of active TB, Th1 cells were 
characterised by a high expression of the activation marker HLA-DR. In contrast, Th22 
cells did not demonstrate activation using this marker during TB disease. Similarly, Th1 
cells were more differentiated in TB disease irrespective of HIV status, while there was 
no difference in the memory phenotype of Th22 cells during different disease states. 
 
Finally, we characterised Mtb peptide-specific CD4+ and CD8+ T cell responses in 
LTBI, active TB and HIV infection. CD4+ T cells did not produce detectable IL-22 
when blood was stimulated with Mtb peptides, and there was also no IL-22 response 
from CD8+ T cells. Th1 cytokines IFN- and TNF- were detectable from CD4+ and 
CD8+ T cells in response to Mtb peptides. Consistent with previous studies, there was 
a higher proportion of individuals with detectable CD8+ responses during active TB 
and HIV co-infection compared to HIV-infected LTBI individuals, but no difference is 
the magnitude of response was observed. Interestingly, HIV infection and TB disease 
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induced similar levels of activation in Mtb-specific CD8+ compared to CD4+ T cells. 
Moreover, active TB and HIV co-infection impaired memory differentiation of Mtb-
specific CD8+ T cells towards a less differentiated profile, compared to LTBI. These 
results confirm that both CD4+ and CD8+ T cells contribute to TB immune responses.  
 
In summary, we confirm that Th22 cells constitutes a substantially portion of CD4+ T 
cell response to Mtb. IL-22 appears to be produced by conventional CD4+ T cells but 
may require specific antigen presentation requirements to optimally induce its 
production. Interestingly, HIV infection during TB disease led to a near absence of 
Th22 cells in blood. Our results warrant further study of the role of Th22 cells in TB 
immunity, which may lead to insights that could assist the development of an effective 
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Tuberculosis (TB) remains on the leading cause of death from an infectious disease globally 
(WHO, 2019). In 2018, approximately 10 million people developed TB, and 1.45 million died 
from the disease (WHO, 2019). HIV is the greatest risk factor for TB illness and death, with over 
250 000 of the people who died from TB in 2018 being HIV-infected.  
 
The World Health Organisation (WHO) has established the “End TB strategy” that aims to reduce 
TB deaths by 90% and TB incidence by 80% by the year 2030, compared to 2015 cases. The 
priorities for the “End TB Strategy” include development of a vaccine to lower the risk of infection, 
and a vaccine or a new drug treatment to cut the risk of TB disease in individuals with latent 
tuberculosis infection (LTBI; WHO, 2019). The only licensed TB vaccine, Bacille Calmette-
Guérin (BCG), is universally administered at birth in TB endemic countries. However, BCG 
provides only partial protection against severe TB in children but does not provide consistent or 
durable protection against adult disease (Mangtani et al., 2014). Therefore, there is a need for a 
safe and more effective TB vaccine to reduce the burden of TB morbidity and mortality and to 
reduce Mycobacterium tuberculosis (Mtb) transmission in both HIV-infected and HIV-uninfected 
populations (Knight et al 2014). In order to develop a more effective TB vaccine, we need to 
understand the type of immunity that confers protection against TB. 
 
In this thesis, I explore features of adaptive immunity to TB in latent and active TB in persons with 
and without HIV infection. My main focus is investigating the contribution of a less well-studied 
subset of T helper cells, Th22 cells, in TB immunity and how HIV infection impacts Th22 immune 
responses. In this introductory chapter, the current knowledge on TB immunity, defects caused by 
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HIV that may lead to increased risk of developing TB, advances in vaccine development and the 
potential role of Th22 cells in Mtb control are reviewed. 
 
1.2 Epidemiology of TB 
1.2.1 Burden of TB disease 
Approximately 1.7 billion people are latently infected with TB and are at risk of developing active 
TB during their lifetime. A global estimate of people with TB disease has been stable over the last 
10 years (range: 9.0 – 11.1 million). The burden of disease varies depending on geographical 
location, and eight countries account for two thirds of TB prevalence: India (27%), China (9%), 
Indonesia (8%), the Philippines (6%), Pakistan (5%), Nigeria (4%), Bangladesh (4%) and South 
Africa (3%) (WHO, 2019). Figure 1.1 shows global incidence of TB in the year 2018. 
 
Rifampicin is the most effective first-line drug against TB. Of the 10 million people who developed 
TB in 2018, 500 000 were infected by rifampicin resistant Mtb (RR-TB), and of these, 78% had 
multidrug-resistant TB (MDR-TB). Among cases of MDR-TB in 2018, 6.2% were estimated to 
have extensively drug-resistant TB (XDR-TB). MDR-TB is defined as resistance to rifampicin and 
isoniazid, while XDR-TB is defined as MDR-TB plus resistance to at least one drug in the 
following two classes of medicines used in treatment of MDR-TB: fluoroquinolones and second-
line injectable agents (WHO, 2019). It is estimated that 3.5% of new TB cases and 18% of 




Figure 1.1: Estimated worldwide tuberculosis incidence rate in 2018.   Taken from the Global 
Tuberculosis Report 2019, World Health Organisation. 
 
The current recommended treatment for cases of drug-susceptible TB is a 6-month regimen of four 
first-line drugs: isoniazid, rifampicin, ethambutol and pyrazinamide. This regimen is highly 
effective against TB (at least 82% treatment success rate) in cases of drug-susceptible TB. 
However, treatment for MDR-TB is longer, more expensive and comprises more toxic drugs. 
Furthermore, MDR-TB and XDR-TB cases have lower treatment success rate (56% and 34%, 
respectively) (WHO, 2019). Moreover, successful treatment does not confer protection against 
relapse or reinfection (Lambert et al., 2003). Recently, the FDA approved a new treatment for 
drug-resistant forms of TB, pretomanid. This drug is approved to be used in combination with 
bedaquiline and linezolid, two other recently approved drugs, and this drug regimen has the 
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The current standard for TB diagnosis is the use of culture-based methods, however, these tests 
have a long turn-around time (up to 12 weeks) (WHO, 2019). Molecular assays are increasingly 
used in combination with culture techniques to reduce time to diagnosis. The Xpert® MTB/RIF 
assay (Cepheid, USA) is currently the only rapid molecular test that is recommended by WHO, 
although microscopy and culture remain essential for treatment monitoring. The Xpert® MTB/RIF 
test can simultaneously detect TB and resistance to rifampicin. Other assays are available for 
testing resistance to rifampicin and isoniazid as well as resistance to fluoroquinolones and 
injectable anti-TB drugs (e.g. line probe assays (LPAs) (WHO, 2019). These tests require sputum 
sample; therefore, it is difficult to effectively diagnose individuals with lack of cavitation (Charmie 
et al., 2010).  
 
Latent TB infection can be diagnosed using IFN- release assays (IGRA), such as 
QuantiFERON®-TB Gold In-Tube. These assays measure the secretion of IFN-γ after stimulation 
with Mtb peptide antigens. WHO recommends IGRA tests for diagnosis of latent TB infection, 
although these tests cannot distinguish between LBTI and active TB disease (Menzies et al., 2008).  
 
1.2.2 HIV and TB co-infection 
HIV infection is the greatest known risk factor for TB, being associated with increased risk of 
active TB development, disseminated TB and high TB mortality (Walker et al., 2013). Globally, 
high HIV prevalence and high TB incidence rates are significantly correlated (WHO, 2019). This 
deadly synergy of HIV and TB is highest in Africa, where 25% of TB patients in 2018 had HIV-
associated TB (WHO, 2019). The risk of TB is increased even within a year of HIV infection, at 
any CD4 count. Factors that may be responsible for the high mortality rate of TB in HIV-infected 
 6 
individuals include: (i) compromised immune responses by HIV leading to rapid TB disease 
progression, and (ii) complication of TB diagnosis as a result of HIV infection, resulting in delayed 
TB treatment (Kwan and Ernst, 2011). Concerning the latter, HIV-associated TB is more likely 
have a false negative result from a TB sputum smear test (WHO, 2019), which could result from 
lack of cavitation in HIV-infected individuals. 
 
HIV co-infection also causes complications for TB treatment. The success rate of TB treatment in 
HIV co-infection patients is lower compared to HIV-uninfected individuals (77% vs 82% success 
rate, respectively) (WHO, 2019). It is thought that antiretrovirals (ARVs), taken for control of 
HIV, interact with anti-TB drugs that could lead to patients having adverse effects such as 
peripheral neuropathy and rash (Dean et al., 2002), and also result in poor ARV retention and 
faster elimination of drugs (Kwan and Ernst, 2011). Studies show that HIV infection increases the 
chances of recurrent TB, especially when CD4 counts are low (Perriens et al., 1991; Pulido et al., 
1997; Mallory et al., 2000). 
 
1.3 TB pathogenesis  
1.3.1 Early events in Mtb infection 
Tuberculosis is an infectious bacterial disease caused by the pathogen Mycobacterium tuberculosis 
(Mtb) (Wolf et al., 2007). Mtb is primarily transmitted by the respiratory route, and typically 
causes disease in the lungs (pulmonary TB), although it can cause disease in most organs 
(extrapulmonary TB). The primary target for Mtb infection is alveolar macrophages (AM) in the 
lungs; the infection results in the engulfment of the bacilli by resident phagocytic cells, alveolar 
macrophages, neutrophils or dendritic cells (DC) (Figure 1.2) (Giacomini et al., 2001). The 
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bacteria then induce the recruitment of macrophages and may trigger granuloma formation 
(Ndlovu and Marakalala, 2016). Upon engulfment of the bacilli, the adaptive immune response is 
then activated by DC trafficking to draining lymph nodes and presenting antigens to T cells 
(Giacomini et al., 2001). B cells, T cells and other cells are then recruited to restrain Mtb bacilli at 
the centre of the granuloma. However, as the disease progresses, necrotic breakdown of granuloma 
cells may result in cavitation of granulomas which could lead the lung to collapse and Mtb bacilli 




Figure 1.2: Early events leading to Mtb infection. Mtb bacilli are inhaled into the lungs, leading to a 
local inflammatory response resulting in the recruitment of monocytes and macrophages and other innate 




It is estimated that at least one third of the world’s population is infected with Mtb, but infection 
does not usually lead to active disease. Infection is controlled in 90% of immunocompetent 
individuals establishing latent infection (LTBI), while progressive primary disease occurs at a rate 
of 2-10% in a lifetime (O’Garra et al., 2013). Given the observed complexity between the host and 
bacterial interaction and outcome, more recent trends in understanding Mtb infection and TB 
disease have moved away from the binary distinction and view LTBI and active TB as stages on a 
spectrum, which include clearance, resistance, subclinical, mild and severe manifestations of TB 
(Barry et al., 2009). 
 
1.3.2 Granuloma formation 
A granuloma is characterized by an organized aggregate of epithelioid macrophages, foamy 
macrophages, and multinucleated giant cells (MGCs), which form by fusion of the plasma 
membranes of multiple macrophages at the centre, surrounded by B and T lymphocytes and other 
cell types including neutrophils, dendritic cells, natural killer (NK) cells, and fibroblasts (Figure 
1.2) (Ndlovu and Marakalala, 2016).  
 
The granuloma was initially believed to contain Mtb bacilli and enable mycobacterial killing. 
However, some studies suggest that granuloma formation creates an environment that may result 
in mycobacterial persistence and dissemination (Ramakrishnan, 2012; Ehlers and Schaible, 2013). 
The heterogeneity of lung granulomas has been demonstrated during both active TB and latent 
tuberculosis infection (LTBI), where some granulomas were sterile, while others contained vastly 
different numbers of bacteria in cynomolgus macaques (Lin et al., 2014; Gideon et al., 2015). 
Sterile granulomas were characterized by a balance of proinflammatory and regulatory cytokines 
 9 
(Gideon et al., 2015), indicating the importance of cytokine responses in the fate of mycobacteria 
in granulomas. 
 
1.4 Immune response to TB 
1.4.1 Innate Immunity 
Cells of the innate system are responsible for initiating the immune response to pathogens. 
Macrophages, dendritic cells (DC) and neutrophils are the primary phagocytes involved in the 
uptake of Mycobacterium tuberculosis in the lung (Walker et al., 2013). 
 
Macrophages 
Following pulmonary Mtb infection, AM are the first cells to encounter the inhaled Mtb bacilli. 
Macrophages can then present Mtb antigens to CD4+ T cells via major histocompatibility complex 
(MHC) II enabling CD4+ T cells to activate AM through cytokines and inhibit bacterial growth 
(Chan et al., 1992; Flynn et al., 1995). Macrophages can also secrete proinflammatory cytokines 
(IFN- and TNF-) and induce a granulomatous inflammatory response (Giacomini et al., 2001). 
Moreover, macrophages can kill Mtb directly via apoptosis (Behar et al., 2011) and autophagy 
(Gutierrez et al., 2004). However, Mtb has developed multiple strategies to escape macrophage 
killing such as inhibiting phagosomal maturation (Sturgill-Koszycki et al., 1994; Toossi et al., 
2012), inhibiting antigen presentation/macrophage activation (Baena and Porcelli, 2009; Grace 
and Ernst, 2016) and inhibiting autophagy (Shin et al., 2010). It is important to note that different 
forms of macrophages exist in the lung and they play different roles in advancing or controlling 
infection (Tripathi et al., 2014). In mice, AM have been shown to be more susceptible to Mtb 
growth compared to interstitial macrophages (IM) (Huang et al., 2018; Cohen et al., 2018).  It is 
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important to note that different forms of macrophages exist in the lung and they play different roles 
in advancing or controlling infection (Tripathi et al., 2014). In mice, AM have been shown to be 
more susceptible to Mtb growth compared to interstitial macrophages (IM) (Huang et al., 2018; 
Cohen et al., 2018). 
 
Dendritic cells 
The primary function of DC is the induction of the antimycobacterial T cell immune response 
(Banchereau and Steinman, 1998; Giacomini et al., 2001). After phagocytosis of Mtb , DCs 
become activated and upregulate co-stimulatory and MHC molecules for enhanced antigen 
presentation and the capacity to stimulate T cells (Henderson et al., 1997; Giacomini et al., 2001). 
DCs then traffic to draining lymph nodes and present antigens to T cells to activate the adaptive 
immune response. However, Mtb can delay activation of the adaptive responses by preventing 





The importance of neutrophils in controlling Mtb infection has been reported. Studies suggest that 
neutrophils play a protective role against Mtb during the early phase of infection (Martineau et al., 
2007; Lowe et al., 2012). Upon Mtb infection, neutrophils rapidly migrate to the lung, phagocytose 
bacilli, and contribute to the early clearance of infection through their antimicrobial peptides 
(Eruslanov et al., 2005; Martineau et al., 2007; Lowe et al., 2012). Indeed, granzyme B expression 
by neutrophils was found in the lung granulomas of Mtb-infected cynomolgus macaques (Mattila 
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et al., 2015). However, neutrophils have also been associated with pathological effects in TB by 
disseminating viable bacteria (Eruslanov et al., 2005; Lowe et al., 2012).   
 
Innate Lymphoid cells (ILCs) 
The involvement of ILCs in the control of Mtb has been investigated. Recently, group 3 ILCs 
(ILC3s) were shown to mediate protective immunity during the acute stage of Mtb infection by 
orchestrating the recruitment of alveolar macrophages in mice (Ardain et al., 2019). Furthermore, 
RNA sequencing of ILC2s and ILC3s from resected human lungs revealed that ILCs are activated 
and recruited to the lung during Mtb infection (Ardain et al., 2019). In addition, ILCs share similar 
characteristics with CD4+ Th cells (Spits et al., 2013) and are able to produce cytokines (IFN-, 
IL-17 and IL-22), which are involved in protective TB immunity (Cupedo et al., 2009; Ardain et 
al., 2019; Cella et al., 2019).  
 
1.4.2 Adaptive Immunity 
CD4+ T cells 
It is well established that CD4+ T cells are critical for immunity against Mtb (Jasenosky et al., 
2015). CD4-deficient mice had higher bacterial burden in the lungs, spleen and liver and increases 
Mtb dissemination (Caruso et al., 1999). Moreover, using MHC class II chimeric mice, it was 
demonstrated that CD4+ T cells must directly detect Mtb infected lung myeloid cells for optimal 
control of intracellular Mtb (Srivastava and Ernst, 2013). In humans, the importance of CD4+ T 
cells is illustrated in the case of HIV infection, which causes progressive CD4+ T cell depletion 
that strongly correlates with increasing risk of TB (Selwyn et al., 1989; Lawn et al., 2002). 
However, TB susceptibility due to HIV infection is likely not limited to CD4+ T cells, with other 
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immune mechanism involving cells of the innate immune system (inhibition of phagocytosis and 
autophagy in macrophages) having been documented (Bell et al., 2017). 
 
CD4+ T cells differentiate into a number of T helper (Th) subsets that produce a range of cytokines 
(Kara et al, 2014). Differentiation of naïve CD4+ T helper cells is induced by the presence of 
various cytokines and is dependent on the expression of transcription factors, effector cytokines, 




Figure 1.3: Diversity of CD4+ T cells and factors that modulate the differentiation of naïve CD4+T 
cells. Th1, Th2, Th9, Th17, Th22, Tfh and Treg lineages are defined based on the expression of transcription 
factors, signature cytokines, and chemokine receptors. Question marks denote properties that are unknown. 
Taken from Knochelmann et al., 2018.  
 
Th1 cells which produce cytokines IFN-γ and TNF-α have been intensively studied and recognised 
as vital in protective TB immunity (Jasenosky et al, 2015). Challenging mice deficient in IFN-γ or 
TNF-α with Mtb resulted in  high bacterial loads, disseminated disease, necrosis and consequently 
rapid death after Mtb challenge (Flynn, 1993; Flynn et al, 1995). In humans, studies have shown 
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an increased prevalence of mycobacterial infections in individuals with genetic defects in the Th1 
pathway compared to the general population (Ottenhoff et al.,1998). Similarly, individuals with 
auto-antibodies against IFN-γ were shown to have increased susceptibility to mycobacterial 
diseases (Kampmann et al., 2005). Furthermore, individuals receiving anti-TNF immunotherapy 
for rheumatoid arthritis or Crohn’s disease had an increased rate of aTB reactivation (Keane et al., 
2001; Harris et al., 2010). Although the importance of IFN-γ is clearly established, it is evident 
that IFN-γ may not be sufficient to protect against TB. This was initially illustrated by the modified 
Vaccinia Ankara virus expressing antigen 85A (MVA85A) vaccine that was designed to enhance 
the protective efficacy of BCG (Tameris et al., 2013).  This vaccine was shown to induce highly 
durable (>1000 days) Ag85A-specific CD4+ Th1 responses but was not effective in TB control in 
phase II clinical trials (efficacy of 17.3%) (Odutola et al., 2012; Tameris et al., 2014). This may 
indicate that Th1 CD4+ T cells alone are not sufficient for control of Mtb.  In fact, evidence shows 
that overproduction of Mtb-specific Th1 responses resulting from PD-1 blockade may increase the 
risk or severity of tuberculosis in mice and humans (Sakai et al., 2016; Chu et al., 2017; Picchi et 
al., 2018; Barber et al., 2019). Therefore, studies have pointed to IFN- independent mechanisms 
of CD4+ T cells protection (Wozniak et al., 2010a; Gallegos et al., 2011; Lu et al., 2019).  
Additional CD4+ T helper subsets such as Th17 and Th22 cells may thus play a role in protective 
TB immunity.  
 
Adoptive transfer of mycobacterial-specific Th17 cells in IFN-γ deficient mice provided protection 
against Mtb challenge (Wozniak et al., 2010a). Furthermore, defective granuloma formation and 
poor immune control of Mtb has been observed in mice lacking IL-17 (Yoshida et al, 2010; Gopal 
et al, 2014). Moreover, IL-17 was also shown to be important in vaccine induced protective 
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immunity in mice (Khader et al., 2007) and NHP (Wareham et al., 2014). In humans, IL-17 CD4+ 
T cells were found to be lower in TB patients compared to Mtb-exposed individuals (Perreau et 
al., 2013; Heidarnezhad et al., 2016) and single nucleotide polymorphisms (SNPs) in IL-17 
resulted in reduced risk of TB disease (Milano et al., 2016; Yu et al., 2017). IL-17 inhibits Mtb 
growth by regulating chemokine receptors (CXCL-1 and CXCL-5) to induce neutrophil-mediated 
inflammation and promote granuloma maturation (Khader et al., 2007; Umemura et al., 2007; 
Yoshida et al., 2010). Moreover, IL-17 was also shown to be important in vaccine-induced 
protective immunity in mice (Khader et al., 2007) and NHP (Wareham et al., 2014). These data 
indicate that Th17 cells play a role in protective immunity against Mtb.  The potential role played 
by Th22 cells is discussed in detail in Section 1.5 below. 
 
CD8+ T cells 
There is a growing body of evidence supporting a protective role for CD8+ T cells in TB. CD8+ 
major histocompatibility complex (MHC) class 1-restricted T cells specific for secreted 
immunodominant Mtb antigens have been identified (Lalvani et al., 1998; Lewinsohn et al., 2006). 
Studies have observed a higher proportion of circulating CD8+ T cells responders to ESAT-6/CFP-
10 in individuals with active TB compared to LTBI individuals, but the magnitude of responses 
are similar (Caccamo et al., 2009; Day et al., 2011; Rozot et al., 2013; Amelio et al., 2019). Mtb-
specific CD8+ T cells display different memory phenotypes between LTBI (TEMRA: 
CD45RA+CCR7−) and active TB individuals (TEM: CD45RA−CCR7−) (Caccamo et al., 2009; 
Rozot et al., 2013). 
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In non-human primates, BCG-vaccinated rhesus macaques lacking CD8+ T cells had significantly 
lower vaccine-induced immunity against TB (Chen et al., 2009). In vitro studies have shown that 
CD8+ T cells are able to kill Mtb-infected macrophages or suppress Mtb growth in macrophages 
through perforin, granulysin and/or Fas-Fas interactions (Stenger et al., 1997; Brookes et al., 2003; 
Andersson et al., 2007; Canaday et al., 2014) by targeting heavily Mtb-infected cells (Lewinsohn 
et al., 2003). Similarly, a subset of CD8+ T cells expressing granulysin is depleted during anti-
TNF therapy, leading to increased risk of reactivating LTBI (Bruns et al., 2009; Miller and Ernst, 
2009).  
 
1.4.3 Unconventional T cells 
Unconventional T cells denote to cells that don’t recognize antigens presented by cell-surface 
proteins of the MHC such as MHC class I or MHC class II. These cells are also referred to as 
donor-unrestricted T cells, and include  T cells, mucosal associated invariant T cells (MAIT) 
and CD1-restricted cells (Beckman et al., 1994; Tilloy et al., 1999; Sieling et al., 2000). 
 
 T cells 
γδ T cells express the γδ TCR and recognize non-protein antigens such as synthetic alkyl 
phosphates and isoprenoids produced by bacteria (Tanaka et al., 1995; Morita et al., 2000). 
Presentation of antigens to γδ T cells is mediated through extracellular pathway that does not 
require antigen uptake, antigen processing, or MHC class I or class II expression (Morita et al., 
1996). γδ T cells secrete a range of effector cytokines including IFN-γ and cytotoxic molecules in 
response to mycobacteria (Barnes et al., 1993; Poggi et al., 2009; Steinbach et al., 2016) and have 
been reported to expand during active tuberculosis (Ness-Schwickerath and Morita, 2011). A 
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subset of  T cells (Vγ9Vδ2) that recognizes microbial phosphorantigens has also been described 
in Mtb infection (Shen et al., 2002). These cells are thought to regulate Mtb infection through the 
release of IFN- and IL-10 (Pinheiro et al., 2012; Chen et al., 2013).  Furthermore, administration 
of phosphoantigen (HMBPP) and IL-2 induced expansion and pulmonary accumulation of 
Vγ9Vδ2 T cells which resulted in reduced Mtb burden in non-human primates (Chen et al., 2013). 
 
Mucosal associated invariant T cells (MAIT) 
Mucosal associated invariant T (MAIT) cells express a semi-invariant TCR (V7.2-Ja33/20/12 in 
humans, paired with a limited number of V chains and can either be activated though recognition 
of MHC class I-related molecule, MR1 (Tilloy et al., 1999; Reantragoon et al., 2012) or by 
cytokines such as IL-12 and IL-18 (Ussher et al., 2014; Suliman et al., 2019). MAIT cells exert 
their function by producing inflammatory cytokines (IFN-, TNF-, IL-17) which can act directly 
on infected cells to inhibit Mtb growth (Gold et al., 2010; Le Bourhis et al., 2010). MAIT cells 
can also mediate perforin-dependent killing of infected cells (Kurioka et al., 2015). Evidence 
shows that these cells are lower in blood of active TB individuals (Le Bourhis et al., 2010; Kwon 
et al., 2015; Coulter et al., 2017) and present in the lungs or pleural effusions of patients with 




There are five types of CD1-restricted T cells divided into three groups: group 1 (CD1a, CD1b and 
CD1c), group 2 (CD1d) and group three (CD1e) (Calabi and Milstein, 1986; Young and Moody, 
2006). All five CD1 types recognize lipid and lipid-associated antigens and present them to T cells. 
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However,  these CD1-restricted T cells may serve different functions, as the CD1 receptors are 
expressed differentially on Langerhans cells and skin resident DCs (mostly CD1a), myeloid DCs 
(CD1b), monocyte-derived DCs, B cells, and Langerhans cells (CD1c) and CD1d on many cell 
types, including macrophages, and epithelial cells (Angénieux et al., 2000; De La Salle et al., 
2005; Roura-Mir et al., 2005; Young and Moody, 2006; Barral and Brenner, 2007; Dougan et al., 
2007). CD1e is the only member of the CD1 group that is not expressed on the surface of APCs 
(Angénieux et al., 2000). The role of CD1-restricted cells in TB control is not clear. Mtb infection 
or immunization with Mtb lipids has been shown to elicit group 1 CD1-restricted T cell responses 
in mice (Felio et al., 2009). Furthermore, group 1 CD1-restricted T cells are cytotoxic and produce 
IFN-γ and TNF-α in response to mycobacterial antigens (Ulrichs et al., 2003; Gilleron et al., 2004; 
Layre et al., 2009). In addition, CD1-restricted cells producing IFN- have been found in higher 
frequencies in Mtb-infected individuals in comparison to healthy controls (Ulrichs et al., 2003). 
Polymorphisms in CD1a and CD1d have been shown to lead to greater susceptibility to TB in 
human cohorts (Seshadri et al., 2014; Taheri et al., 2019). 
 
B cells 
Unlike T cells, the role of B cells in controlling Mtb was traditionally thought to be minimal, 
although antibody responses have been detected in both LTBI and TB disease (Wilkinson et al., 
1997, 1998; Achkar et al., 2015). Indeed, B cell-deficient mice presented with higher bacterial 
burdens when challenged with Mtb (Vordermeier et al., 1996). Moreover, passive transfer of 
monoclonal antibodies against Mtb components have been shown to be effective in reducing 
bacterial load in spleens and lungs, reduced weight loss and resulted in long-term survival of mice 
after Mtb infection (Teitelbaum et al., 1998; Hamasur et al., 2004; López et al., 2009; Balu et al., 
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2011). Recently, IgM and class-switched IgG and IgA antibody responses were detected in a cohort 
of individuals who appeared to be resistant to TB infection (‘resistors’), namely household contacts 
who were exposed to Mtb yet remained persistently IGRA and TST negative (Lu et al., 2019). 
These studies highlight B cells as underestimated players in Mtb control.   
 
1.5 Characteristics of IL-22 and its potential role in TB immunity 
1.5.1 Biology of IL-22 
Interleukin (IL)-22 is a member of the IL-10 family of cytokines, and it is produced by a variety 
of cells, including T cells (Th17, Th22, Th1 and γδ T cells) and a range of innate cells (innate 
lymphoid cells (ILCs) and NK cells) (Rohan Dhiman et al., 2009; Witte et al., 2010; Cella et al., 
2019). IL-22 signals through a type 2 receptor (IL-22R), which is composed of two heterodimeric 
subunits, IL-22R1 and IL-10R2 (Logsdon et al., 2004). IL-22R is expressed on non-hematopoietic 
cells, particularly epithelial cells (Yoon et al., 2010), with a few reports of upregulation on 
macrophages (Rohan Dhiman et al., 2009; Treerat et al., 2017). The transcription factor aryl 
hydrocarbon receptor (AHR) has been shown to be involved in the production of IL-22 in both 
mice and human (Trifari et al., 2009; Basu et al., 2012). Exogenous cytokines IL-6, IL-23, TNF 
and IL-1 have also been shown to promote IL-22 production (Duhen et al., 2009; Trifari et al., 
2009; Basu et al., 2012; Plank et al., 2017).  
 
IL-22 signalling is mainly mediated by signal transducer and activator of transcription (STAT)-3, 
STAT-1 and STAT-5 phosphorylation (Figure 1.4) (Dudakov et al., 2015).  Activation of 
receptor-associated Jak1/Tyk2 kinases activation is induced by ligation of the IL-22-IL-22R1-IL-
10R2 complex, Jak1/Tyk2 kinases then phosphorylates IL-22 receptors and STAT proteins. 
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Evidence suggests that IL-22 can also signal through p38 and the mitogen-activated protein (MAP) 
kinase pathways (Dudakov et al.,2015).   
 
 
Figure 1.4:  Receptors and Jak-STAT molecules of the IL-10 family of cytokines. IL-22 receptor is 
composed of two subunits: the IL-10R2 subunit and the IL-22R1 subunit. The IL-10R2 is shared with the 
receptors for IL-10, IL-26, IL-28, and IL-29; while the IL-22R1 subunit itself can also pair an IL-20R2 
subunit forming the receptor for IL-20 and IL-24. Taken from Dudakov et al., 2015. 
 
1.5.2 IL-22 function 
The primary function of IL-22 is to preserve mucosal barriers and protect the host from microbial 
pathogens in the skin, respiratory tract and digestive tract (Sonnenberg et al.,2011). In addition to 
its role in infectious disease, the importance of IL-22 in protection and regeneration of epithelial 
tissues has been widely studied in cancers, inflammatory skin diseases, hepatitis, pancreatitis, 
colitis, and thymic injury (Dudakov et al.,2015).   
 
The role of IL-22 in infectious disease was first described in mouse studies performed with 
Citrobacter rodentium infection, where IL-22 was shown to enhance epithelial cell proliferation 
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in the gut as IL-22 knockout mice displayed significant damage to colonic epithelial cells 
(Sugimoto and Ogawa, 2008; Basu et al., 2012). Moreover, infection of IL-22 deficient mice with 
C. rodentium resulted in intestinal epithelial damage, a high bacterial burden and mortality (Zheng 
et al., 2008). Similarly, in mice infected with Klebsiella pneumoniae, IL-22 neutralisation resulted 
in an exacerbated bacterial dissemination when IL-17 was also absent (Aujla et al., 2008). In 
influenza infection, IL-22 deficient mice displayed aggravated lung injury (Pociask et al., 2013) 
and severe impairment in the regeneration of tracheal epithelial cells (Kumar et al., 2013) 
compared to wild type mice. Although IL-22 has a protective role in several tissues, uncontrolled 
expression can cause tissue damage and chronic inflammation, which could lead to inflammatory 
skin diseases such as psoriasis or development of several types of cancer (Schmechel et al., 2008; 
Zhu et al., 2012). 
 
1.5.3 IL-22 and TB 
IL-22 was reported to be non-essential for the control of Mtb in mouse models (Wilson et al., 
2010; Khader et al., 2011; Behrends et al., 2013; Segueni et al., 2016), using lab Mtb strains 
H37Rv and Erdman. IL-22 was shown to be produced mainly by IFN-γ-secreting cells in mice 
(Behrends et al., 2013). However, a more recent study by Treerat and colleagues described a 
protective role of IL-22 against a hyper-virulent Mtb strain (HN878) in an aerosol model of 
infection, where IL-22 knockout mice displayed higher bacterial burdens during the chronic stage 
of Mtb infection (Treerat et al., 2017). Furthermore, IL-22 produced by NK cells was shown to 
inhibit the growth of Mtb by enhancing phagolysosomal fusion (Dhiman et al., 2009).  Indeed, the 
administration of IL-22 at the time of BCG vaccination resulted in reduced bacterial burden and 
enhanced CD4+ T cell response after Mtb challenge in mice by inhibiting expansion of induced 
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Tregs, thus enhancing Ag-specific T cell responses (Dhiman et al., 2012). IL-22 was 
downregulated in the blood but upregulated in the lungs of rhesus monkeys during severe TB (Qiu 
et al., 2008). In humans, soluble IL-22 has been detected at sites of pulmonary and extra-
pulmonary TB (Scriba et al., 2008; Matthews et al., 2011a), and a SNP in the IL-22 promoter has 
been linked to TB susceptibility (Zhang et al., 2011).  Furthermore, isoniazid preventive therapy 
(IPT) and TB treatment enhanced mycobacteria-specific IL-22 production in the periphery (Zhang 
et al., 2014; Suliman, Geldenhuys, John L. Johnson, et al., 2016), suggesting that reduction of 
antigen load in the site of infection by anti-TB drugs leads to restored IL-22 responses in blood. In 
bovine TB, an IL-22 gene expression signature was the dominant surrogate of BCG vaccine-
induced protection following infection with M. bovis (Bhuju et al., 2012). Moreover, in vitro 
expression of PPD-specific-IL-22 was higher in cattle naturally infected with M. bovis compared 
to uninfected cattle (Aranday-Cortes et al., 2012).  
 
1.6 The effect of HIV on TB pathogenesis 
1.6.1 Alteration of Mtb-specific CD4+ T cells 
The risk of developing TB is estimated to be between 16-27 times greater in people living with 
HIV than among those without HIV infection (WHO, 2019). The obvious reason for increased TB 
risk is that HIV infection causes progressive loss in CD4+ T cells which is associated with 
increased risk of developing TB (Sonnenberg et al., 2005). However, the risk of developing TB 
increases within one year of HIV infection and occurs even at preserved CD4 count (Sonnenberg 
et al., 2005). Therefore, studies have investigated preferential depletion and dysfunction of Mtb-
specific CD4+ T cells in HIV infection. 
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Geldmacher et al. have reported that Mtb-specific peripheral CD4+ T cells are preferentiality 
depleted in HIV infection compared to cytomegalovirus (CMV)-specific CD4+ T cells 
(Geldmacher et al., 2010). HIV infection causes a reduction in the frequency and absolute number 
of circulating CD4+ T cells in individuals with preserved CD4 count (Riou, Bunjun, et al., 2016; 
Bunjun et al., 2017; Day et al., 2017). Several studies have reported a decreased frequency of Mtb-
specific responses in bronchoalveolar lavage (BAL) of HIV-infected compared to uninfected 
individuals (Kalsdorf et al., 2009; Jambo et al., 2011; Bunjun et al., 2017). HIV infection has also 
been shown to distort the balance of Mtb-specific Th subsets, as lineage-defining transcription 
factor profiles were skewed in HIV-infected individuals (Riou et al., 2016). Furthermore, SIV 
infection was reported to alter effector T cell phenotypes and dysregulated T cell homeostasis, 
which was associated with reactivation of LTBI in macaques (Bucşan et al., 2019). However, a 
study by Bunjun et al. reported that the absolute number of CD4+ T cells in bronchoalveolar lavage 
(BAL) is similar between HIV-infected and uninfected individuals with LTBI, and this could be 
attributed to infiltration of CD4+ T cells into the airways (Bunjun et al., 2017). These data 
demonstrate that HIV infection causes depletion and dysfunction of Mtb-specific CD4+ T cells 
both in the blood and at the disease sites, thereby compromising Mtb immunity.  
 
1.6.2 Dysfunction of CD8+ T cells 
CD4+ T cells provide help to CD8+ T cells (Matloubian, Concepcion and Ahmed, 1994; Serbina, 
Lazarevic and Flynn, 2001). Therefore, CD4+ reduction and dysfunction during HIV infection 
may result in CD8+ T cell dysfunction. HIV infection may result in impaired degranulation and 
proliferative capacities of Mtb-specific CD8+ T cells (Kalokhe et al., 2015). HIV infection also 
results in chronic activation that may lead to premature exhaustion of CD8+ T cells (Breton et al., 
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2013; Amelio et al., 2019). Further studies to elucidate the impact of HIV on Mtb-specific CD8+ 
T cells are warranted. 
 
1.6.3 Impairment of innate immunity 
Evidence supports the assertion that HIV infection impairs innate immunity, permitting the 
persistence of Mtb infection. Neutrophils in the blood of ART-naïve HIV-infected individuals 
were shown to be less effective in restricting Mtb growth compared to HIV-uninfected persons 
(Lowe et al., 2015). Furthermore, HIV infection impairs the ability of neutrophils to phagocytose 
Mtb by reducing CD16 and CD35 mediated opsonophagocytosis in human serum (Bangani et al., 
2016). In addition, HIV infection impairs neutrophil activation, respiratory burst, phagocytosis, 
and microbial killing capacity, particularly at low CD4 counts and high viral load (Lowe et al., 
2012).  
 
In a study by Jambo et al., HIV was reported to preferentially infect AM as they harboured a 
substantial amount of HIV in the BAL (Jambo et al., 2014). The phagosomal proteolysis of AM 
was impaired in HIV-infected cells (Jambo et al., 2014a, 2014b). In TB and HIV co-infected 
individuals, activation of the innate immune system (monocytes, interleukin-6, tumour necrosis 
factor-ɑ and colony-stimulating factor) was associated with mortality (Janssen et al., 2017).  In 
vitro studies demonstrated that HIV infection can augment mycobacterial virulence factors and 
impair their ability of macrophages to contain Mtb growth (Imperiali et al., 2001; Pathak et al., 
2010). Moreover, HIV accessory protein Nef can interfere with phagosome biogenesis to inhibit 
macrophage phagocytosis (Mazzolini et al., 2010) and can block the maturation of 
autophagosomes resulting in the inhibition of autophagy (Kyei et al., 2009; Killian et al., 2012). 
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Moreover, HIV infection has been reported to inhibits TNF-α dependent macrophage apoptosis by 
inhibition of TNF-α promoter activation (Patel et al, 2009;). 
 
Of note, HIV and Mtb are both recognized by DC-specific intercellular adhesion molecule 3 
grabbing nonintegrin (DC-SIGN, CD209) and its homolog, DC-SIGN-related (DC-SIGNR or L-
SIGN), and this is likely to influence host immunity and bacterial persistence in co-infected 
persons (Tailleux et al., 2003; da Silva et al., 2011). Indeed, HIV was shown to interfere with Mtb 
antigen presentation in an experimental system using human immature DCs coinfected with HIV 
and Mtb, as demonstrated by reduced Mtb antigen processing and inhibition of autophagy (Singh 
et al., 2016).  
 
HIV infection has also been found to deplete human ILCs in blood (Kløverpris et al., 2016). In 
macaques, SIV infection resulted in loss of ILCs within gut associated lymphocyte tissue (GALT)  
and a persistent loss of IL-17-producing ILCs in the jejunum (Xu et al., 2010; Li et al., 2014). 
Moreover, Hueber et al. observed a 3-fold depletion of ILC3 in the colon of SIV/SHIV-infected 
infant rhesus macaques (RM) compared to uninfected (Hueber et al., 2019). In addition, HIV 
infection was shown to deplete ILC3 in human blood with correlated with HIV disease progression 
(Zhang et al., 2015). Furthermore, using humanized mice model, Zhang et al.,  demonstrated that 
HIV depleted ILC3 through CD95/FasL-mediated apoptosis which required activation of 
plasmacytoid dendritic cells (pDCs) and induction of IFN (Zhang et al., 2015). It is not known 
whether ILC depletion occurs in the lungs and may compromise TB immunity. 
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Interestingly, TB has also been shown to contribute to HIV pathogenesis (Whalen et al., 1995; 
Badri et al., 2001; Meng et al., 2016). This is supported by reports that show that during active 
TB, HIV-infected individuals have viral loads increased up to 160-fold compared to non-TB 
symptomatic HIV-infected patients, suggesting that TB may promote HIV replication in co-
infected individuals (Goletti et al., 1996; Toossi et al., 2001). Furthermore, Zhang et al 
demonstrated an increase in HIV-1 p24 levels in BAL fluid from Mtb-infected lung sites compared 
with uninfected lung sites in HIV-TB co-infected patients (Zhang et al., 1995). Additionally, it has 
been shown that active TB causes an increase in expression of HIV coreceptors CXCR4 and CCR5 
on CD4+ T cells, thereby increasing the HIV target cells (Juffermans et al., 2001).  
 
1.6.4 IL-22 and HIV 
Depletion of IL-22-producing CD4+ T cells has been reported to be one of factors associated with 
HIV immunopathogenesis. Th22 and Th17 cells were shown to be depleted in blood and tissue 
mucosa in HIV-infected individuals, and  correlated positively with microbial translocation (Kim 
et al., 2012) and loss of IL-17 and IL-22-producing lymphocytes was found to be associated with 
damage to the colonic epithelial barrier during SIV infection (Klatt et al., 2012). Microbial 
translocation is defined as a loss of epithelial integrity and mucosal immune deficiency, allowing 
bacterial products to enter the circulation, leading to immune activation, the latter playing a key 
role in the immune-pathogenesis of HIV infection (Brenchley et al., 2006). Further evidence 
supporting the importance of IL-22-producing CD4+ T cells in maintaining mucosal homeostasis 
during HIV and SIV infection has been reported. In a longitudinal study performed in rhesus 
macaques, SIV-infection induced a loss and a severe dysfunction in intestinal IL-17, IL-22, and 
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IL-17/IL-22 producing CD4+ T cells which was not evident in blood and lymph node (Ryan et al., 
2016).  
 
It has been shown that CCR6+ CD4+ T cells, which characterize primarily cells of a Th22 and 
Th17 phenotype (i.e. cells expressing the cytokines IL-22 and IL-17), express high levels of HIV 
co-receptor CXCR4 (Alvarez et al., 2013). Kim and colleagues reported that a higher proportion 
of Th22 cells express the main HIV co-receptor CCR5, compared Th1 cells, as well as integrin 
47, which has been associated with increased HIV susceptibility (El Hed et al., 2010; Monteiro 
et al., 2011; Kim et al., 2012; Sivro, Schuetz, Sheward, Joag, Yegorov, Lenine J. Liebenberg, et 
al., 2018). Furthermore, CCR6+ cells lack production of CCR5 ligands (-chemokines) which 
have been shown to induce autocrine protection against HIV (El Hed et al., 2010; Alvarez et al., 
2013). CD4+CCR6 cells have also been associated with enriched HIV DNA and increased HIV 
replication (Cleret-Buhot et al., 2015; Gosselin et al., 2017; Planas et al., 2017). However, in 
contrast to these findings, it was recently demonstrated that SIV did not preferentially infect Th17 
cells, Th1 cells, Th2 cells, or Tregs, but infected polarized memory CD4+ T cells equally in vivo 
(Lai et al., 2019). 
 
1.7 Advances in TB vaccine development  
The Bacille Calmette-Guérin (BCG) vaccine, which was developed almost 100 years ago, remains 
the only licensed vaccine for preventing TB (WHO, 2019). Although effective in preventing 
childhood and extra-pulmonary TB (60–80% protection), BCG provides inconsistent protection 
against pulmonary TB and it is not effective when given in adulthood (Fine, 1995; Trunz et al., 
2006; Bo et al., 2008). The reasons behind variable protection provided by BCG against pulmonary 
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TB are unclear. HIV infection further complicates BCG vaccine-induced protection. Indeed, HIV-
infected infants had lower CD4 responses after BCG vaccination compared to HIV-uninfected 
infants (Mansoor et al., 2009). Moreover, BCG is a live attenuated mycobacterial vaccine, thus 
posing a risk of local or disseminated BCG disease and immune reconstitution inflammatory 
syndrome (IRIS) (Hesseling et al., 2007). Therefore, the WHO has recommended that HIV-
infected infants should no longer be vaccinated with BCG (WHO, 2007). We urgently need an 
effective TB vaccine that can either replace or supplement BCG (Gupta et al., 2018). 
  
There are currently 12 TB vaccines in development, four in phase 1, eight in phase 2a/b, and three 
in phase 3 (Figure 1.5) (WHO, 2019). Scientist employ different strategies for developing new  
TB vaccines, to provide for different target groups (infants, adults, individuals with LTBI, or HIV-
infected individuals) (Andersen and Urdahl, 2015). These include subunit (e.g. H4:IC31), killed 
mycobacterial whole cells or cell extract (e.g. RUTI), live attenuated (e.g. MTBVAC), live 
recombinant (e.g. MVA85A) and DNA (e.g. Ag85A DNA) vaccines (WHO, 2019).  Subunit 
vaccines usually consist of immunodominant components enhanced using adjuvants. These 
vaccines have many advantages, including safety, low cost, easy preparation, high yield and high 
purity. The disadvantages of subunit vaccines are that the short duration of immunogenicity, poor 
memory immunity, the use of adjuvants and the process of antigen screening to identify 
immunodominant antigens is complex (Zhu et al., 2018). Killed/inactivated vaccines could 
potentially be safe and effective against preventing TB disease. However, these vaccines are likely 
to provide a short period of protective immunity and required multiple inoculations and high doses 
(Gong et al., 2018). Live attenuated and live recombinant vaccines are advantageous because they 
can possess a large antigen repertoire and potentially mimic natural infection, therefore they can 
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potentially elicit broad immune responses. The main drawback of live vaccines is safety, as there 
is a potential risk of virulence recovery and complications in immunocompromised individuals 
(Hesseling et al., 2007; Ui et al., 2017). While DNA vaccines are much safer, they still require 
optimization to obtain the desired efficacy against TB (Zhu et al., 2018).  
Recently, a promising vaccine candidate M72/AS01E demonstrated an efficacy of 54% in the 
primary analysis and  50% in the final analysis (three years follow-up) of a phase 2b clinical trial 
conducted in three African countries (Kenya, South Africa, and Zambia) involving HIV-uninfected 
individuals (Van Der Meeren et al., 2018; Tait et al., 2019). This is a subunit vaccine derived from 
two immunogenic Mtb antigens (32A and 39A) adjuvanted with AS01E (Skeiky et al., 1999; Al-
Attiyah et al., 2004). M72/AS01E vaccination induced IgG antibodies and polyfunctional M72-
specific CD4+ T cell responses (Gillard et al., 2016; Kumarasamy et al., 2018; Van Der Meeren 
et al., 2018). Although the efficacy of M72/AS01E remains to be tested in HIV-infected 
individuals, studies have shown that this vaccine is safe in HIV-infected individuals and induced 
polyfunctional M72-specific CD4+ T cell responses (Thacher et al., 2014; Kumarasamy et al., 
2016, 2018). Finally, M72/AS01E candidate vaccine offers an opportunity to investigate the 
correlates of immune protection as the lack of understanding of correlates of protection is a major 
challenge facing development of new TB vaccines (Sakai et al., 2014). 
Another interesting advance in TB vaccine development studies is BCG revaccination. A recent 
study by Nemes et al. reported that BCG revaccination of adolescents who had received neonatal 
BCG vaccine provided an efficacy of 45.4% against Mtb infection as measured by sustained QFT 
conversion (30 month) and 20.1% efficacy against Mtb infection based on initial QFT conversion 
(Nemes et al., 2018). However, other studies conducted in Brazil showed no efficacy against Mtb 
infection or TB disease, indicating that the success of BCG revaccination may be dependent on 
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study populations, age and the epidemiology of TB (Rodrigues et al., 2005; Barreto et al., 2011). 
Indeed, effectiveness of primary BCG vaccination has been shown to variable in different 
populations (Mangtani et al., 2014). The advantage of BCG revaccination is that it is a highly cost-
effective intervention as BCG is already licenced.  
 
 
Figure 1.5: New TB vaccines currently in the global development pipeline. Taken from 
https://www.newtbvaccines.org/tb-vaccine-pipeline/. 
 
Most studies investigate Th1 responses to determine the immunogenicity of TB vaccine candidates 
(Soares et al., 2008; Tameris et al., 2014; White et al., 2015; Norrby et al., 2017). However, IFN-
 secretion has been shown to be a poor correlate of protection in BCG-vaccinated mice (Majlessi 
et al., 2006; Mittrücker et al., 2007) and individuals testing positive for IFN- release assays 
(IGRA) have up to 10% of developing TB in their lifetime (O’Garra et al., 2013). 
 
Limited studies have examined vaccine induced IL-22 production. BCG-specific IL-22 responses 
were detected in BCG-revaccinated adults (Suliman et al., 2016) and BCG-vaccinated infants had 
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higher BCG-specific IL-22 responses compared to unvaccinated in blood (Nissen et al., 2017).  
BCG vaccination also induced IL-22 production in bronchoalveolar lavage fluid (Gupta et al., 
2018) and recombinant IL-22 was shown to enhance the protective efficacy of BCG vaccine by 
decreasing the number of immunosuppressive Tregs (Dhiman et al., 2012). These studies indicate 
that investigating the IL-22 contribution to TB control may lead to new insights that could 
potentially aid in TB vaccine development.  
 
Overall, there have been exciting advances is TB vaccine development with multiple promising 
new TB vaccine candidates. There are also vaccines currently in animal models that will enter 
human trials soon (WHO, 2019). However, many questions remain unanswered, such as different 
immune correlates of protection, environmental factors that influence the success of TB vaccines, 
the relationship between the human host and M. tuberculosis, the best route of vaccine delivery, 
and whether is it possible to develop vaccines that will clear Mtb.   
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1.8 Aims and Objectives 
The overall aim of this project was to study T cell immune responses to TB, with a focus on the 
contribution of Th22 cells to TB immune responses through characterising Mycobacterium 
tuberculosis-specific IL-22-producing CD4+ T cells in detail and examining the impact of TB 
disease and HIV infection on these cells.  
 
Objective 1: To examine factors that lead to Mtb-specific IL-22 production and further 
characterise of Mtb-specific Th22 cells 
Rationale:  In studies performed in our laboratory, we have observed a very low to no IL-22 
detection in PBMC, whilst detection is robust in whole blood (Bunjun et al., submitted). We further 
demonstrated that IL-22 production in PBMC could be recovered when autologous PBMCs were 
added to whole blood. This suggests that there are factors in blood absent in PBMC which are vital 
for IL-22 production. Since the characteristics of Th22 cells are not fully defined, we investigated 
factors that influence Mtb-induced IL-22 production and further characterise Th22 cells. We 
determined the T cell subsets that produce IL-22 in response to Mtb stimulation, assessed whether 
IL-22 is produced through “bystander” effect or requires TCR engagement, and investigated 
soluble factors that could lead to Mtb-specific IL-22 production in PBMCs.  
 




Objective 2: To characterise Mtb-specific Th22 cells and investigate the effect of tuberculosis 
disease and HIV co-infection  
Rationale: A distinct subset of CD4+ T cells producing IL-22 have been identified, ‘Th22’ cells. 
A recent study in mice described a protective role for IL-22 during the chronic stage of Mtb 
infection against a clinical strain of Mtb. There has been limited research into the effect of HIV 
and TB co-infection on Th22 cells, which may provide insights into the role they play in human 
disease. In a previous study performed in our laboratory, we observed high frequencies of 
mycobacteria-specific Th22 cells, and demonstrated that HIV infection results in the depletion of 
these Th22 cells (Bunjun et al., submitted). In this study, we sought to extend these investigations 
to both latent and active TB and  HIV co-infection, and compared the quality and quantity of Mtb-
specific Th22 cells in persons with HIV infection with active TB disease, HIV infection with latent 
TB infection, TB disease in the absence of HIV infection, and latent TB infection without HIV 
infection. We tested the hypothesis that the combination of TB disease and HIV infection would 
result in extensive reduction on Mtb-specific Th22 cells. 
 
This portion of the study is presented in Chapter 3. 
 
Objective 3: To compare the magnitude and phenotype of CD8+ and CD4+ responses to Mtb 
during TB disease and/or HIV infection  
Rationale: Whilst many studies have investigated the importance of CD4+ T cells in the control 
of Mycobacterium tuberculosis, relatively fewer have characterized CD8+ T cells. Evidence 
suggests that both CD4+ and CD8+ T cells play a role in successful immune control of 
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Mycobacterium tuberculosis infection. Therefore, we sought to investigate the contribution of 
CD8+ T cells compared to CD4+ T cells in TB immune responses and study the impact of TB 
disease and HIV infection on CD8+ T cells. 
 




Optimization of IL-22 detection and characterization of Mtb-specific CD4+ T 
cells producing IL-22 
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Interleukin-22 (IL-22) is a relatively recently described cytokine that belongs to the IL-10 family 
of cytokines. IL-22 has been shown to be produced by a range of adaptive and innate cells, 
including CD4+ T cells, γδ T cells, NKT cells and innate lymphoid cells (ILCs) (Sonnenberg et 
al., 2011; Ronacher et al., 2018). IL-22 is involved in tissue repair (Pickert et al., 2009; McGee et 
al., 2013), immunity to bacterial infections (Valeri and Raffatellu, 2016) as well as viral, fungal, 
and parasitic infections (Dudakov et al., 2015; Brias et al., 2016). IL-22 exerts its function by 
inducing the production of antimicrobial peptides and proteins such as -defensins, the S100 
family of peptides, Reg3, calprotectin and calgranulin A (Lin et al., 2017; Moyat et al., 2017; 
Tyler et al., 2017). IL-22 signaling also regulates chemokine expression to orchestrate the 
recruitment of immune cell subsets to sites of infection (Whittington et al., 2004; Aujla et al., 
2008). In addition, IL-22 promotes tissue proliferation, regeneration, and healing of epithelial cells 
(Witte et al., 2010; Sabat et al., 2014; Dudakov et al., 2015). 
 
IL-22 was initially thought to be a Th17 cytokine due to co-expression with IL-17 in mice (Liang 
et al., 2006). However, human studies showed that that IL-22 is mainly produced by a distinct 
subset of CD4+ T cells named Th22 cells (Duhen et al., 2009; Eyerich et al., 2009; Trifari et al., 
2009). The production of IL-22 is thought to be partially regulated by the transcription factor aryl 
hydrocarbon receptor (AHR) (Trifari et al., 2009; Basu et al., 2012). Exogenous cytokines IL-6, 
IL-23, TNF and IL-1 have been shown to promote IL-22 production (Duhen et al., 2009; Trifari 
et al., 2009; Plank et al., 2017). However, the characterization of IL-22 producing cells, the signals 
leading to IL-22 production and the range of ways in which IL-22 functions in immunity remains 
incompletely described, warranting a better understanding of Th22 cells.   
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In the context of TB infection, there is evidence to suggest a possible role of IL-22 in Mtb immunity 
(Treerat et al., 2017), but to date Mtb-induced IL-22 production has been understudied in humans. 
In this Chapter, we describe the optimization of IL-22 detection in human blood, determining 
factors that contribute to Mtb-specific IL-22 production, and characterizing some aspects of the 
biology of Mtb-specific IL-22 producing CD4+ T cells. 
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2.2 Material and methods 
2.2.1 Study participants  
Blood samples were collected from healthy adult donors with LTBI recruited from the University 
of Cape Town. The exclusion criteria for the study participants were: pregnancy, age <18 years, 
weight <50kg and any acute or chronic illness. LTBI was diagnosed based on a positive IFN-γ 
release assay (QuantiFERON®-TB Gold In-Tube) or positive responses to Early secretory 
antigenic target (ESAT-6) and culture filtrate protein 10kDa (CFP-10) peptides pool and no 
symptoms of aTB. All participants gave written, informed consent. The study was approved by the 
University of Cape Town, Faculty of Health Sciences Human Research Ethics Committee (HREC 
051/2018). 
 
2.2.2 Antigens and Mitogens 
The following antigens were used in this study: 
Bacillus Calmette–Guérin (BCG) is the current licensed vaccine against Mtb and consists of live 
attenuated Mycobacterium bovis. The BCG used in this study was from M. bovis Danish strain 
1331 (SSI, Denmark). BCG and Mtb have numerous protein antigens in common, however BCG 
lacks a genomic region (RD-1) that confers virulence to Mtb and virulent M. bovis (Mahairas et 
al., 1996). 
 
ESAT-6/CFP-10 are encoded by the region of difference 1 (RD-1) genes, Rv3875 and Rv3874, 
respectively.  CFP-10 and ESAT-6 are specific to Mtb and play an important role in Mtb virulence 
(Forrellad et al., 2013). The peptide pools used in this study were made from 15mer peptides 
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overlapping by 10 amino acids and covering the entire length of Rv3874 and Rv3875. Seventeen 
peptides made up ESAT-6 and 16 made up CFP-10 (Peptide Synthetics, UK). 
 
Mycobacterium tuberculosis lysate (MtbL) from Mtb strain H37Rv (BEI Resources) contains the 
cell contents from log-phase Mtb. MtbL is a mixture of all the proteins, lipids and carbohydrates 
present in the cell. 
 
Gamma-irradiated Mtb whole cells (-irr Mtb) from Mtb strain H37Rv (BEI Resources) contains 
Mtb bacilli grown to late-log phase in glycerol-alanine-salts medium and inactivated by exposure 
to 2.4 megaRads of ionizing gamma irradiation using a 137Cs source.  
 
Phorbol myristate acetate/Ionomycin (PMA/Iono): PMA is a specific activator of Protein Kinase 
C (PKC) that is commonly used with ionomycin, a membrane permeable calcium ionophore that 
promotes transport of calcium ions Ca2+ into treated cells, to activate the transcription factors NF-
κB and nuclear factor of activated T cells (NFAT), thus inducing cytokine production (Schindler 
and Baichwal, 1994; Pinton et al., 2008). 
 
Staphylococcus enterotoxin B (SEB) is an enterotoxin produced by the gram-positive bacteria 
Staphylococcus aureus. SEB is also a superantigen that induces polyclonal T cell activation and 
cytokine production (McLeod et al., 1998). 
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Phytohemagglutinin (PHA) is a lectin from the bean Phaseolus vulgaris, that triggers calcium 
dependent signaling pathways leading to NFAT activation and cytokine production, by binding to 
sugars on glycosylated surface proteins and crosslinking them (Fortin et al., 2001). 
 
These antigens and mitogens were used at concentrations previously reported (Hanekom et al., 
2004) or were titrated in our laboratory for specific assays, and final concentrations used are 
described below. 
 
2.2.3 Blood collection and stimulation 
Blood was collected in sodium heparin tubes and processed within four hours of collection. Unless 
stated otherwise, whole blood assays were performed according the protocol described previously 
(Hanekom et al., 2004). Briefly, 0.5 ml of heparinized whole blood was stimulated with Mtb cell 
lysate (strain H37Rv, 20 μg/ml, BEI Resources), an Mtb-specific peptide pool [(4 μg/ml), 
consisting of 17 and 16 peptides covering the entire ESAT-6 and CFP-10, respectively], live 
bacillus Calmette-Guerin (BCG) (MOI of 4, Mycobacterium bovis Danish strain 1331, SSI), 
gamma-irradiated Mtb whole cells (Strain H37Rv, 600 μg/ml, BEI Resources), Phorbol Myristate 
Acetate (PMA; 0.01 µg/ml; Sigma-Aldrich) and Ionomycin (25 µg/ml; Sigma-Aldrich), 
Staphylococcal Enterotoxin B (SEB; 5 µg/ml; Sigma-Aldrich) or Phytohemagglutinin (PHA; 10 
µg/ml; Thermo Scientific) at 37 °C for a total of 12 h in the presence of anti-CD28 and anti-CD49d 
(1 μg/ml each; BD Biosciences) co-stimulatory antibodies. After 7 h, brefeldin A (10 µg/ml; 
Sigma-Aldrich) was added to block cytokine release by inhibiting protein transport from the Golgi 
apparatus to the endoplasmic reticulum. Red blood cells were lysed with Alternative Lysing 
Solution (ALS; 150 mM NH4Cl, 10 mM KHCO3, 1 mM Na4EDTA) and washed twice with 15 ml 
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PBS. The cell pellet was subsequently stained with LIVE/DEAD Fixable Violet Dead Cell Stain 
(Molecular Probes) or LIVE/DEAD® Fixable Near-Infrared Stain (Invitrogen) and cells washed 
twice with 15 ml PBS. Cells were then fixed using FACS Lysing solution (BD Biosciences) for 
10 min and stained immediately.  
 
2.2.4 Peripheral blood mononuclear cells (PBMC) isolation and stimulation 
Heparinized blood collected in BD Vacutainer® sodium heparin tubes was separated using Ficoll-
Hypaque (Sigma Aldrich) density gradient centrifugation to isolate peripheral blood mononuclear 
cells (PBMC). Briefly, room temperature Ficoll-Hypaque (Sigma-Aldrich) was added to Leucosep 
tubes (Greiner) and centrifuged at 900 x g for 1 min to pass the Ficoll through the separation disc. 
Whole blood was then added to Leucosep tubes containing Ficoll and centrifuged at 900 x g for 
10 min to allow for separation. The layer containing PBMC was transferred to 50 ml tubes and 
washed twice with RPMI 1640 (Sigma) supplemented with 1% fetal calf serum (FCS, HyClone). 
PBMC were then rested for 4 h at 37 ºC, 5% CO2 in RPMI 1640 supplemented with 10% FCS 
(R10). The cells were then washed with R10 before transferring to 5 ml FACS tubes for 
stimulation. PBMC (2 x106) were stimulated with Mtb cell lysate (strain H37Rv, 25 μg/ml, BEI 
Resources) in 500 μl of R10 or conditioned media (see Section 2.2.5) for a total of 16 h with BFA 
addition after 7 h. All assays were performed on freshly isolated PBMC. 
 
2.2.5 Treating PBMC with conditioned media  
Whole blood was stimulated as described in Section 2.2.3. Blood was centrifugated and the plasma 
from the stimulated or non-stimulated blood was added to RPMI to prepare 20% Mtb-stimulated 
plasma (Mtb/plasma) or 20% non-stimulated plasma (NS/plasma), respectively. Freshly isolated 
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PBMC were then resuspended in R10, RPMI with autologous 20% Mtb/plasma or RPMI with 20% 
NS/plasma prior to stimulation with MtbL as described in Section 2.2.4 above.  
 
2.2.6 Flow Cytometry 
Antibodies 
The antibodies listed in Table 2.1 were used for surface or intracellular staining. All antibodies 
used were titrated to identity the optimal concentration for detection of each marker. This titer was 
selected based on saturation, the signal to noise ratio and staining index. A fluorescence minus one 
(FMO) control (i.e. staining with all antibodies except the one of interest) was included to guide 
our gating strategy. Antibody titrations were performed for every new lot of antibody.  
 
Surface and Intracellular staining 
For surface staining, fixed cells were transferred to 96-well v-bottom plates and washed three times 
with 200 μl of FACS wash buffer (2% FCS in phosphate buffered solution (PBS)). The plate was 
centrifuged at 800 x g for 5 min at 4 °C and the supernatant discarded. Cells were then resuspended 
in 50 μl of a surface antibody mix in FACS wash buffer and incubated in the dark for 20 min at 
room temperature, followed by washing the cells three times with 200 μl of FACS wash buffer 
again. Cells were then resuspended in 200 μl of Perm/Wash buffer (BD Biosciences) and incubated 
in the dark for 30 min at room temperature. The plate was centrifuged at 800 x g for 5 min at 4 °C, 
the supernatant discarded, and the cells resuspended in 50 μl of an intracellular antibody staining 
mix in Perm/wash buffer and incubated in the dark for 30 min at room temperature. Cells were 
washed three times with Perm/Wash buffer and resuspended in 150 μl of Cell Fix (BD 
Biosciences).  
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Table 2.1 Antibodies used for flow cytometry 
 
Acquisition and data analysis 
Stained cells were acquired on a four-laser BD Fortessa (Figure 2.1) and analyzed using FlowJo 
(v10, TreeStar). A positive cytokine response was defined as at least twice the background (i.e. 
Markers Fluorophore Clone Manufacturer Function Staining 
 
 
Viability marker APC-Cy7  Invitrogen Exclusion Surface 
Viability marker Pacific Blue  Invitrogen Exclusion Surface 
CD14 PE-Cy5.5 Tuk4 Invitrogen Lineage Surface 
CD3 BV650 OKT3 BD Biosciences Lineage ICS 
CD4 ECD T4   Beckman Coulter Lineage Surface 
CD8 Qdot 705 3B5   Life Technologies Lineage Surface 
CD56 PE-Cy7 NCAM 16.2 BD Biosciences Lineage Surface 
CD161 APC HP-3G10 eBioscience Lineage Surface 
IFN- Alexa fluor 700 B27 BD Biosciences Cytokine ICS 
IL-22 eFluor 450 22URTI eBioscience Cytokine ICS 
IL-22 PE 22URTI eBioscience Cytokine ICS 
IL-22 APC 22JOP eBioscience Cytokine ICS 
IL-22 APC 142928 R & D systems Cytokine ICS 
IL-17 FITC BL168 Biolegend Cytokine ICS 
IL-17 Alexa fluor 647 N49-653 BD Biosciences Cytokine ICS 
Pan  PE IMMU510 Beckman Coulter Lineage Surface 
 
 
TCR V7.2 BV510 3C10 Biolegend Lineage Surface 
TCR V11 FITC C21 Beckman Coulter Lineage Surface 
TCR V24 PE C15 Beckman Coulter Lineage Surface 
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unstimulated cells) and a minimum of 10 events. To define the phenotype of cytokine-producing 
cells, a cutoff of 20 events was used. 
 
Compensation 
In order to accurately determine primary fluorescent signals for each detector, we determined the 
fluorescent contribution of each fluorophore in each detector and calculated the compensation 
matrix (i.e. the fluorescent signal percentages subtracted from each primary detector).  
Figure 2.1: The filter configuration of the BD Fortessa used in the study. The filter arrangement is 
shown for each of the four lasers, with two octagons and two trigons. 
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Briefly, individually stained compensation beads (anti-mouse Ig-κ or anti-rat Ig-κ beads; BD 
Biosciences) corresponding to each antibody-conjugate used in the flow cytometry panel were 
prepared for each flow cytometry run. One drop of compensation beads (~ 40 ul) was incubated 
with each antibody (at the optimally determined titer) in a 5 ml polystyrene tube for 20 min at 
room temperature. The excess antibody was washed off by adding 3 ml PBS and centrifuging at 
800 x g for 5 min. The supernatant was decanted, and the beads resuspended in 200 μl of Cell Fix 
buffer (BD Biosciences). 
 
2.2.7 Determining the TCR Vβ repertoire of  
cytokine-positive cells 
The IOTest® Beta Mark TCR Vβ Repertoire Kit 
(Beckman Coulter) was used to determine the 
TCR Vβ repertoire of Mtb-specific IFN- or IL-
22-producing CD4+ T cells. Briefly, cells from 
Mtb lysate stimulated whole blood were stained 
with CD3 BV650 (OKT3; BD Biosciences), 
CD4 PerCP-Cy5.5 (L200; BD Biosciences), 
IFN- Alexa700 (B27; BD Biosciences) and IL-
22 APC (22JOP; eBioscience™), and each of the 
eight vials containing mixtures of conjugated 
TCR vβ antibodies corresponding to 24 different 
specificities that represent up to 70% of normal human TCR vβ Repertoire (Table 2.2).  
 
Table 2.2: List of TCR V- antibodies in tubes 
A-H (Beckman Coulter)   
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2.2.8 Lymphocyte-specific protein tyrosine kinase (Lck) inhibition 
Whole blood from healthy individuals was incubated with increasing concentrations (1 μM to 60 
μM) of Lck inhibitor (7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-
ylamine, Sigma) for 30 min prior to cell stimulation (Rapecki et al., 2002; Schade et al., 2008.). 
Whole blood was then stimulated as described in Section 2.2.4., followed by analysis of cytokine 
production. To determine the percentage inhibition, we used the following formula: frequency of 
cytokine-producing CD4+ T cells at a given Lck inhibitor concentration divided by frequency of 
cytokine-producing CD4+ T cells without Lck inhibitor, multiplied by 100.  
 
2.2.9 Statistical analysis 
Statistical tests were performed using Prism (v6; GraphPad). Nonparametric tests were used for 
all comparisons. The one-way ANOVA Friedman test and Kruskal-Wallis test with Dunn’s 
Multiple Comparison test was used for multiple comparisons and the Mann–Whitney U test and 
Wilcoxon matched pairs test were used for unmatched and paired samples, respectively. Chi-
square tests were used to analyze categorical data to compare proportions of individuals with 
detectable cytokine responses. A p value of < 0.05 was considered statistically significant. SPICE 
version 5.1 was used to analyze cytokine co-expressing populations and to perform permutation 
tests. Pestle was used for background subtraction and generating SPICE data.  
 
2.3 Results 
2.3.1 Optimization of IL-22 cytokine production in whole blood 
To optimize detection of IL-22 production, we first compared which IL-22 antibody clones provide 
the optimal detection (Figure 2.2A). Blood stimulated with MtbL was stained with three IL-22 
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antibody clones: IL-22 PE (22URTI; eBioscience™), IL-22 APC (22JOP; eBioscience™), and IL-
22 APC (142928; R & D) (Figure 2.1A). We detected higher frequencies of IL-22-producing 
CD4+ T cells using IL-22 antibody clones 22URTI and 22JOP, compared to clone 142928 
(frequency: 2.33%, 2.38% vs. 1.14%, respectively). We selected IL-22 antibody clone 22URTI to 
use for all subsequent experiments.  
 
To determine the optimal concentration of antibody, we titrated all antibodies included in flow 
cytometry panels. Figure 2.2B and C shows titration of IL-22 antibody, cells were stained with 
increasing volume of the antibody (0 µl - 2.5 µl) and no stimulation and FMO controls were 
included. We then compared the frequency and median fluorescent intensity (MFI) of IL-22-
producing CD4+ T cells in response to Mtb lysate stimulation at different IL-22 titers and 
calculated the staining index ((MFI pos-MFI neg)/ 2*SD MFI neg) and signal to noise ratio (MFI 




Figure 2.2 (next page): Comparison of IL-22 antibody clones and titration of IL-22 antibodies. (A) 
Representative flow cytometry plots showing IL-22 production by CD4+ T cells using different antibody 
clones. Antibody clones tested and the conjugated fluorochromes used are indicated on top of each set of 
plots. (B) Representative flow cytometry plots showing frequencies of IL-22-producing CD4+ T cells at 
different antibody titers after whole blood stimulation with MtbL. (C) Determining optimal antibody titer.  
The dotted line indicates the chosen titer. Ab, antibody, MFI: median fluorescence intensity, SD: standard 
deviation, SI: staining index, S/N: signal to noise, MtbL: Mycobacterium tuberculsosis lysate, NS: no 
stimulation, FMO: Fluorescent Minus One. Calculations: Signal to noise ratio = MFI pos/MFI neg; 





Next, we investigated the ability of different mitogens including Phorbol myristate 
acetate/Ionomycin (PMA/Iono), Staphylococcus enterotoxin B (SEB) and phytohemagglutinin 
(PHA) to induce IFN-, IL-22 and IL-17 production to identify an optimal positive control for each 
cytokine, particularly IL-22 (Figure 2.3). Figure 2.3A shows representative flow cytometry plots 
showing MtbL-, PMA/Iono-, SEB- and PHA-responding IFN-, IL-22 and IL-17 responses. The 
highest IFN- production was detected when blood was stimulated with PMA/Ionomycin (median: 
8.1%) compared to SEB (median 1.3%, p = 0.005) or PHA (median 1.03%, p=0.002). We detected 
similar and generally low frequencies of IL-22-producing CD4+ T cells when blood was 
stimulated with PMA/Ionomycin (median: 0.17%) and SEB (median: 0.19%) and both responses 
were significantly higher than PHA responses (median 0.03%; p = 0.004 and p = 0.004, 
respectively). In contrast to the poor IL-22 responses induced, PHA and PMA/Iono induced robust 
production of IL-17 (medians: 0.7% and 0.6%; respectively), with significantly lower CD4+ cells 
producing IL-17 in response to SEB (median 0.1%; p=0.002 and p=0.01, respectively). As 
PMA/Ionomycin was the only mitogen able to induce production of all tested cytokines (IFN-, 
IL-22 and IL-17), albeit at low levels for IL-22, this mitogen was chosen as a positive control. It 
is interesting that similar IL-22 responses were detected when blood was stimulated with PMA 
and SEB. This is surprising as SEB is known to trigger only 20% of TCRs through src kinase Fyn, 
while PMA/IONO bypasses TCR and activates PKC, NF-κB and NFAT (Schindler and Baichwal, 
1994; Pinton et al., 2008; Janik et al., 2015), thus PMA would be expected to induce higher IL-22 
production compared to SEB. 
In our experiment we included stimulation with MtbL and measurement of IFN-, IL-22 and IL-
17 responses to MtbL (Figure 2.3). Interestingly, we observed a similar magnitude of Mtb-specific 
IFN- and IL-22 producing CD4+ T cells in response to this stimulation (median: 0.59% and 
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0.62%; respectively). MtbL also induced the highest frequencies of IL-22-producing cells, greater 
than any of the mitogens tested. In contrast, IL-17 producing CD4+ T cells were poorly detectable 
in response to MtbL stimulation compared to IFN- and IL-22 (median: 0.01%; p = 0.0003 and p 




Figure 2.3: Identifying an optimal positive control for detecting IL-22 production from CD4+ T cells. 
(A) Representative flow cytometry plots showing IFN-, IL-22 and IL-17 responses after stimulation with 
MtbL, PMA/Iono, SEB and PHA. (B) Comparison of the frequency of IFN-, IL-22 and IL-17 when 
stimulated with different mitogens and MtbL (n=10). Medians are depicted. NS: no stimulation. Statistical 
comparisons were performed using a one-way ANOVA Friedman test. * p < 0.05, ** p < 0.01, *** p < 
0.001, ****p < 0.0001. 
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It is interesting that higher IL-22 responses were detected after stimulation with Mtb lysate 
compared to PMA/IONO. One plausible explanation would be that IL-22 detected after Mtb lysate 
stimulation is resulting from cytokine production induced in other cell types, however, 
experiments in chapter 3 section 2.4, page 61 indicate that Mtb induced IL-22 responses are indeed 
specific and do not represent bystander activation. 
 
We next sought to determine whether similar cytokine profiles were generated in response to 
different types of Mtb antigens, and thus compared blood stimulated with gamma-irradiated whole 
cell Mtb (-irr Mtb), live mycobacteria (M. bovis BCG) or an Mtb peptide pool based on ESAT-6 
and CFP-10 proteins. No differences in the magnitude of IL-22, IFN- or IL-17 responses were 
observed between the different “complex” mycobacterial antigens tested (i.e. Mtb cell lysate, 
gamma-irradiated Mtb and BCG) (Figure 2.4A&B). In contrast, IL-22 production was barely 
detectable in response to Mtb peptide stimulation (Figure 2.4C), with only 2/11 donors with latent 
Mtb infection exhibiting an IL-22 response, at a frequency of <0.05%. All donors were positive 
for IFN- responses (median 0.18%) and 3/11 donors had IL-17 responses. These data indicate that 
IL-22 is readily detectable to complex mycobacterial antigen preparations but poorly detectable 
when using Mtb peptides, suggesting that antigen processing and presentation requirements for 
IL-22 may differ from IFN- induction and that IL-22 production may be mediated through non-
TCR stimulation of other cell types. This is expanded on further in chapter 3.  
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2.3.2 Factors that contribute to Mtb-specific IL-22 production in PBMC compared to 
whole blood 
MtbL stimulation leads to a similar magnitude of IL-22 and IFN- production when employing a 
whole blood assay. However, previous data from our laboratory shows that IL-22 is poorly 
detectable in PBMC compared to whole blood (Bunjun et al., submitted). Interestingly, addition 
of fluorescently-labeled PBMC into autologous whole blood resulted in full recovery of IL-22 
responses from CD4+ T cells derived from PBMC (Bunjun et al., submitted). This suggests that 
PBMC do indeed contain the cells that are able to produce IL-22 in response to Mtb stimulation, 









Figure 2.4: Comparison of the frequency of IFN-, IL-22 and IL-17-producing CD4+ T cells in 
response to different mycobacterial antigen formulations. (A) Representative flow cytometry plots 
showing IFN-, IL-22 and IL-17 responses after stimulation with MtbL, -irr Mtb, and BCG. (B) 
Comparison of the frequency of IFN-, IL-22 and IL-17 responses to different antigens (n=5). (C) 
Comparison of the frequency of IFN-, IL-22 and IL-17 after stimulation with ESAT-6/CFP-10 peptides 
(n=11). NS: no stimulation. The bar represents the median. Statistical comparisons were performed using 
a one-way ANOVA Kruskal–Wallis test. ** p < 0.01. 
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To investigate whether soluble mediators present in whole blood that may be absent in PBMC are 
responsible for inducing IL-22 production from CD4+ T cells, we used conditioned media to 
determine whether IL-22 production requires plasma proteins present in whole blood but not in 
PBMC. We measured the magnitude of IFN- and IL-22-producing CD4+ T cells detected using 
a whole blood assay compared to PBMC stimulation when PBMC are supplemented with 
conditioned media consisting of either 20% Mtb-stimulated plasma (Mtb/plasma), 20% non-
stimulated plasma (NS/plasma) or 10% FCS in RPMI (Figure 2.5A). The whole blood assay 
enabled robust detection of cytokines (IFN- and IL-22) in response to MtbL stimulation in all 
eight donors (Figure 2.5B&C). However, the frequency of IFN- producing CD4+ T cells was 
significantly lower (median ~5 fold) when PBMC were stimulated with MtbL (median: 0.46% vs 
0.09%, respectively; p = 0.0117) (Figure 2.5C). The difference was even more dramatic for IL-
22 responses in PBMC, where Mtb-specific CD4+ T cells producing IL-22 were approximately 
~8 fold lower (median: 0.38% in blood vs 0.05% in PBMC; p = 0.0002) (Figure 2.5C). 
Supplementing PBMC with conditioned media did not significantly improve IFN- production 
(median: 0.11% for NSP and 0.16% for SP) (Figure 2.5C). Interestingly, we observed a slight 
restoration of IL-22 production when PBMC were supplemented with Mtb/plasma conditioned 
media compared to R10 (median: 0.20% vs 0.05%; ~ 4-fold increase p = 0.0161). This increase 
was not observed when PBMC were supplemented with NS/plasma (median: 0.07% for NSP vs 
0.05% for FCS; p = ns) (Figure 2.5C).  
Figure 2.5 (next page): Frequency of Mtb-specific CD4+ T cells in PBMC compared to whole blood. 
(A) Schematic representation of method (B) Flow cytometry plots of IFN- and IL-22 production after 
stimulation with MtbL. NS: no stimulation. (C) Summary graph of the frequency of cytokine responses. 
Medians are depicted. Statistical comparisons were performed using a one-way ANOVA Friedman test. * 
p < 0.05, ** p < 0.01, *** p < 0.001, ****p < 0.0001. FCS: fetal calf serum, NSP: non-stimulated plasma, 





To ensure that the partial restoration of IL-22 production observed in the presence of 
Mtb/conditioned plasma was not solely due to additional MtbL present in the stimulated plasma, 
we defined the dose-response curve of IL-22 production in response to increasing concentrations 
of MtbL (from 10 to 40 µg/ml) in three donors. Maximal IL-22 production was observed at 10 
µg/ml, thus the partial restoration of IL-22 responses observed when conditioned media was used 
is not due to increased MtbL antigen availability (Figure 2.6). These results suggest that Mtb 
antigen-induced soluble factors secreted by cells present in whole blood but absent in PBMC may 
influence IL-22 production, although restoration remains partial and it is likely that additional 
factors influence IL-22 induction in PBMC.  
Altogether, these experiments show that IL-22-producing CD4+ T cells constitutes a substantial 
portion of Mtb immune responses in whole blood. However, these cells are hardly detectable in 
PBMC. In addition, unlike IFN- responses, IL-22 responses were not induced following 
stimulation with Mtb peptides. These data raise several questions: (i) Does IL-22 production 
originate from unconventional T cells? and (ii) Is IL-22 production mediated via a T cell receptor 
(TCR)-independent pathway, rather than being induced by CD4+ T cells upon engagement of 
cognate antigen presented to the TCR? (Boyman et al., 2010).  
 
In order to address these questions, we next determined whether IL-22 production was mediated 
thought TCR triggering (i.e. Mtb antigen being directly recognized by the TCR on responding 
CD4+ T cells), we inhibited the TCR pathway by blocking Lck, a tyrosine kinase critical for early 
propagation of TCR signalling, using increasing concentrations of the Lck inhibitor 7-cyclopentyl-
5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-ylamine. Using whole blood from five 
healthy donors with latent Mtb infection, we found that both IFN- and IL-22 expression were 
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inhibited upon Lck inhibition, in a dose-dependent manner. Interestingly, the ED50 (efficient dose 
causing 50% of maximum effect) for IL-22 inhibition was 2.6 times lower compared to the ED50 
for IFN- inhibition (7.5 µM and 19.5 µM, respectively; Figure 2.7). Of note, cytokine co-
expression profile indicates that on a small proportion of IL-22 is co-expressed with IFN-g, and 
this is further explored in chapter 3. The observed inhibition is most likely specific as it has been 
shown that lck blocking with 7-Cyclopentyl-5-(4-phenoxyphenyl) 7Hpyrrolo[2,3-d] pyrimidin-4-
ylamine leads to reduction of aCD3/CD28 induced cytokine production but not PMA/IONO 
induced cytokine production (Rapecki et al., 2002; Schade et al., 2008).” These data demonstrate 
that IL-22 production from CD4+ T cells is TCR-dependent.  
  
Figure 2.6: Titration of MtbL in PBMC. (A) Representative flow cytometry plots showing CD4+ 
IFN- and IL-22 responses when PBMC are stimulated with different concentrations of MtbL. NS: no 




2.3.3 Characteristics of Mtb-specific IL-22 producing CD4 T cells  
It has been shown that a variety of immune cells including conventional T cells (recognizing 
peptide antigens presented by MHC molecules) and unconventional T cells (recognizing 
nonpeptide antigens, functioning as a bridge between innate and adaptive responses) have the 
ability to produce IL-22 (Sonnenberg et al., 2011; Ronacher et al., 2018). Thus, we investigated 
Figure 2.7: Impact of TCR blocking on IFN- and IL-22 production. (A) Representative flow 
cytometry plots showing Mtb-specific IFN- and IL-22 responses in the presence of different 
concentrations of Lck inhibitor 7-Cyclopentyl-5-(4-phenoxyphenyl) 7Hpyrrolo[2,3-d] pyrimidin-4-
ylamine. (B) Summary graph (n=5) showing the proportion of IFN- or IL-22 producing CD4+ T cells 
relative to whole blood stimulation in the absence of Lck inhibitor. Medians and interquartile ranges are 
depicted. Vertical arrows show ED
50
. Nonlinear regression curve fit used. 
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IL-22 and IFN-γ production from a range of T cell subsets in whole blood, including mucosal-
associated invariant T (MAIT) cells,  T cells, Natural Killer T (NKT) cells, CD4+ T cells and 
CD8+ T cells. Cells were gated on live lymphocytes that were CD3+, and then defined as NKT 
(CD56+),  (CD56-TCR+), MAIT (CD56-TCR-V7.2+CD161+), CD4 (NKT-TCR-
MAIT-CD8-CD4+) and CD8 (NKT-TCR-MAIT-CD4-CD8+) T cells (Figure 2.8A). In 10 
healthy donors tested for cytokine responses, all cell subsets assessed produced IFN-γ when 
stimulated with Mtb lysate. In contrast, in most donors (7 out of 10), IL-22 was exclusively 
produced by CD4+ T cells, with only 3 donors demonstrating a minor contribution of either MAIT 
or  cells to the total IL-22 response from CD3+ cells (Figure 2.8B). Of note, the majority of 
MAIT and  T cells are CD4- (Figure 2.8C), indicating that our gating strategy used in previous 
experiments did not include IL-22 from these T cell sources. Thus, conventional CD3+CD4+ T 
cells appear to be the major source of IL-22 in response to Mtb antigens.  
 
Lastly, we compared the V repertoire usage of IL-22 and IFN- producing CD4+ T cells in blood 
from five healthy donors with latent Mtb infection using IOTest® Beta Mark TCR Vβ Repertoire 
Kit (Beckman Coulter). Figure 2.9A shows representative flow plots of nine out of 24 vβ 
measured. The panel of 24 monoclonal antibodies to TCR V families stained approximately 61% 
of CD4+, 40% of CD4+IFN-+ and 62% of CD4+IL-22+. We observed a similar distribution of 
TCR Vβ subsets between Mtb-specific IL-22 and IFN- producing CD4+ T cells as well as in the 
total CD4+ compartment. TCR V usage ranged from median values of 0.2% for V23 to 13.6% 
for V2, indicating non-random V usage. Interesting, in all donors, Vβ2 and Vβ5.1 accounted 
for more than 5% of the total Vβ usage in Mtb-specific IL-22 and IFN- producing CD4+ T cells 
(median: 13.6% and 10.4 for Vβ2, 8.5% and 6.7% for Vβ5.1, respectively; Figure 2.9B). 
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Similarly, Vβ2 and Vβ5.1 were highly expressed in total CD4 compartment (median: 10.0% for 
Vβ2 and 7.2% for Vβ5.1, Figure 2.9C). Cumulative data (Figure 2.9C) shows similar TCR usage 
between IFN- and IL-22-producing CD4+ T cells, although there are slight differences on an 
individual level (Figure 2.9C). The similar distribution of TCR between IFN-g and IL-22 
producing CD4+ T cells is interesting as these cells represent distinct subsets of CD4+ T cells 
(discussed in chapter 3 below) with minimal co-expression of IFN- and IL-22. There was also 
preferential usage of Vβ1, Vβ8, Vβ17 and Vβ22 by Mtb-specific IL-22 and IFN- producing CD4+ 
T cells, as well as total CD4+ T cells, with at least two out of five donors expressing more than 
2.5% of these TCR Vβ families.  
 
These data show that IL-22 and IFN--producing CD4+ T cells belong to the same families of  
T cells as indicated by a similar TCR usage. Moreover, there were no differences in TCR V usage 
between Mtb-specific CD4+ T cells and total CD4+ T cells, indicating that Mtb does not induce 






Figure 2.8: Contribution of different T cell subsets to Mtb-specific response. (A) Representative flow 
cytometry overlay plots showing IFN- and IL-22 production in different T cell (CD3+) subsets: NKT 
(CD56+),  (CD56-TCR+), MAIT (CD56-TCR-V7.2+CD161+), CD4 (NKT-TCR-MAIT-CD8-
CD4+) and CD8 (NKT-TCR-MAIT-CD4-CD8+) cells. (B) Summary graph of the contribution of 
distinct T cell subsets to cytokine responses. Medians and interquartile ranges are depicted. (C) Expression 




Figure 2.9: TCR V repertoire of IFN- and IL-22 producing CD4+ T cells. (A) Representative flow cytometry plots showing 9/24 V 
antibodies on total CD4+ T cells, IFN- and IL-22 producing CD4+ T cells (B) Bar graph showing TCR distribution on each individual and (C) 






Peripheral blood mononuclear cell (PBMC) are typically used to investigate cellular immune 
responses. While PBMC-based assays allow cryopreservation of sample for later use, these 
types of assays require larger volumes of blood samples, as well as extensive processing, that 
could affect certain cell populations (Kuleshova et al., 2001). Thus, whole blood assays are an 
attractive alternative, requiring smaller blood volumes, being easy and rapid to process, and 
maintaining a more physiological environment (Silberer et al., 2008; Deenadayalan et al., 
2013; Silva et al., 2013). However, one disadvantage of whole blood assay is that the samples 
require immediate stimulation, although they can be fixed and stored after stimulation, for later 
batch staining (as was performed in Chapter 3 and 4). Previous studies have reported 
differences in cytokine production from PBMC compared to whole blood assays (Silberer et 
al., 2008; Deenadayalan et al., 2013; Silva et al., 2013). Here, the whole blood assay allowed 
robust detection of IFN- (median: 0.46%) and IL-22 (median: 0.38%)-producing CD4+ T cells 
in response to Mtb stimulation. IFN- responses were 5-fold lower in PBMC compared to 
whole blood but were still detectable. However, we observed extremely low to absent IL-22 
production in PBMC (median: 0.05%). The lack of IL-22 production in PBMC could be 
explained by multiple factors: i) IL-22 producing cells might be lost/impaired during PBMC 
extraction (Grievink et al., 2016), ii) plasma proteins or Mtb antigen-induced soluble factors 
from cell types in whole blood not present in PBMC could be necessary to induce IL-22 
production and iii) particular antigen-presenting cells and/or costimulatory signals from innate 
cells may be required to induce Th22 responses. Our laboratory recently demonstrated that 
adding fluorescently-labeled PBMC to whole blood before Mtb stimulation resulted in the 
recovery of IL-22 responses in PBMC, indicating that lack of IL-22 responses was not 
attributed to loss of CD4+ T cells producing IL-22 in PBMC (Bunjun et al., submitted). 




plasma from Mtb-stimulated blood only modestly improved IL-22 detection from PBMC, 
suggesting that bystander soluble factors are not sufficient to trigger IL-22 responses (Figure 
2.5). However, it is also possible that insufficient plasma was used, resulting in a reduced 
effect.” (Figure 2.5). Further studies are required elucidate which physiological environment 
is needed for optimal IL-22 production.  
 
A range of cell types of the innate and adaptive immune response have been reported to produce 
IL-22 (Dhiman et al., 2009; Toussirot et al., 2018; Cella et al., 2019). In our work, we show 
that conventional () CD4+ T cells are the predominant source of Mtb-specific IL-22. 
Interestingly, whilst IL-22 responses were readily detectable upon stimulation with complex 
mycobacterial antigens (i.e. Mtb cell lysate, gamma-irradiated Mtb and BCG), Mtb peptides 
(ESAT-6/CFP-10) did not elicit IL-22 responses, further suggesting that adequate antigen 
processing and presentation (Magee et al., 2012) and/or cytokine co-stimulation may be 
necessary to induce IL-22 secretion (Boyman, 2010). A previous study in our laboratory also 
demonstrated that PPD stimulation results in higher responses than ESAT6 and CFP10 but 
lower responses than live BCG stimulation (Bunjun et al., under review). It is also possible 
that non-peptide moieties, only present in complex antigen (such as lipids or lipoproteins), may 
mediate IL-22 production. Indeed, it has been reported that the production of IL-22 by CD4+ 
T cells may be induced upon CD1a triggering in humans (De Jong et al., 2010; Otsuka et al., 
2018). Of note, group 1 (CD1a, b and c) CD1-restricted T cells specific for microbial lipid 
antigens display similar  TCR to peptide specific T cells (Grant et al., 1999). Our data 
showing that Mtb-specific IL-22 production is TCR-dependent and that the TCR V usage in 
IL-22-producing cell is comparable to IFN--producing cells suggest that conventional 
(although not necessarily classically-restricted) CD4+ T are the source of IL-22. To 




further experiments. For example, to determine which cell subsets are required to induce the 
production of IL-22 in response to Mtb, cells such as neutrophils or dendritic cells abundant in 
whole blood, these cells could be depleted before stimulation or PBMC could be supplemented 
with these cells, to determine the effect on IL-22 production. To further investigate the 
restriction of Th22 cells, experiments blocking MHC Class II or CD1 molecules could be 
conducted.  
 
Overall, the data presented in this chapter highlights novel features regarding Th22 cells 
compared to Th1 cells. It is possible that Mtb-specific Th22 cells recognize non-peptide or 
modified peptide antigen, or require a specific activation pathway and other requirements for 
the detection of these cells in vitro, a reason why they have been relatively understudied 
compared to Th1 and Th17 cells. Understanding these unusual features will be key to studying 
these cells further, determining the role they may play in TB immunity, and how we may 
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TB is the leading cause of death from an infectious disease worldwide, with 10 million TB 
cases per year and 1.6 million deaths in 2018 (WHO, 2019). South Africa is one of the eight 
countries that together account for two thirds of all TB cases globally (WHO, 2019). Although 
TB is curable, the development of drug-resistant TB is a public health crisis and WHO 
estimates that 3.5% of new TB cases and 18% of previously treated cases in 2018 had multidrug 
resistant (MDR)-TB (WHO, 2019). Moreover, approximately one quarter of the world’s 
population is latently infected with Mycobacterium tuberculosis (WHO, 2019). In 
immunocompetent individuals, the risk of progression from infection to active TB disease is 
2–10% in a lifetime, illustrating that the human immune system can control Mtb in most cases 
(O’Garra et al., 2013). Bacillus Calmette-Guérin (BCG) is the only licensed TB vaccine and 
protects against disseminated TB in children but provides variable protection against highly 
prevalent pulmonary tuberculosis (PTB) in adults (Fine, 1995; Trunz et al., 2006; Bo et al., 
2008). Therefore, there is an urgent need for new and effective TB vaccines, and recent 
progress in clinical trials is promising (Nemes et al., 2018; Tait et al., 2019). 
 
Understanding the immune responses required to control Mtb will aid in development of 
improved vaccines against TB (Sakai et al., 2014). It is well established that CD4+ T cells, 
particularly Th1 cells producing the cytokines IFN-γ and TNF-α, are critical for immunity 
against Mtb (Jasenosky et al., 2015). It is also clear that Th1 immunity alone is not sufficient, 
as IFN- has been reported to be a poor correlate of BCG vaccination-induced protection 
against tuberculosis in mice (Majlessi et al., 2006; Mittrücker et al., 2007). Furthermore, IFN-
-independent mechanisms of CD4+ T cell mediated control of Mtb infection have been 
documented (Wozniak et al., 2010b; Gallegos et al., 2011; Lu et al., 2019). Thus, other CD4+ 




There is growing interest in the cytokine IL-22 and its role in TB immunity. IL-22 belongs to 
the IL-10 family of cytokines and its receptor is composed of two heterodimeric subunits, IL-
22R1 and IL-10R2 (Logsdon et al., 2004). IL-22 mainly targets non-hematopoietic cells, 
namely epithelial cells and fibroblasts in tissues (Dudakov et al., 2015), but expression of the 
IL-22 receptor has also been reported to be upregulated on macrophages (Dhiman et al., 2009; 
Treerat et al., 2017). IL-22 was initially reported to be dispensable for Mtb control in mouse 
models (Wilson et al., 2010; Behrends et al., 2013). Recently, however, a protective role for 
IL-22 in TB immunity was described in a murine model, where IL-22 deficient mice displayed 
greater bacterial burdens after aerosol infection with a virulent clinical strain of Mtb, HN878 
(Treerat et al., 2017). In humans, soluble IL-22 has been detected at sites of extra-pulmonary 
tuberculosis (Matthews et al., 2011a), and a higher concentration of IL-22 was observed in 
bronchoalveolar lavage fluid (BALF) of individuals with active TB compared to healthy donors 
(Scriba et al., 2008). Moreover, IL-22 has been shown to inhibit intracellular M. tuberculosis 
growth in macrophages (Dhiman et al., 2009), and a polymorphism in the IL-22 promoter has 
been linked to TB susceptibility (Zhang et al., 2011). 
 
IL-22 is produced by a variety of cells, including T cells (Th17, Th1 and γδ T cells) and a range 
of innate cells (ILCs) and NK cells) (Dhiman et al., 2009; Witte et al., 2010; Toussirot et al., 
2018; Cella et al., 2019). In humans, IL-22 is mainly produced by a distinct subset of CD4+ T 
cells, named Th22 cells (Duhen et al., 2009; Eyerich et al., 2009; Trifari et al., 2009). Our 
laboratory recently showed that IL-22-producing CD4+ T cells contribute a substantial portion 
to the mycobacterial response during latent TB infection (LTBI; Bunjun et al., submitted). 
These mycobacteria-specific Th22 cells were depleted during HIV infection to a similar extent 
as Th1 cells, emphasizing their potential importance in protective immunity to TB.  In this 




co-infection. Our aims were to investigate the contribution of Th22 cells to TB immune 
responses, characterize Th22 cells further to gain insights into their function, and examine the 
impact of TB disease and HIV infection on Th22 cells, in comparison to Th1 and Th17 cells. 
Our findings confirm that Mtb-specific IL-22 is produced by Th22 cells and makes up a 
substantial contribution to TB immune responses. We demonstrate for the first time that IL-22 
production is dependent on TCR engagement but may require alternative co-stimulatory 
molecules or antigen presenting cells. Strikingly, Mtb-specific Th22 cells were severely 
diminished in patients with both HIV infection and TB disease. 
 
3.2 Material and methods 
3.2.1 Study participants  
Blood samples were collected from 72 individuals recruited from the Ubuntu Clinic, 
Khayelitsha, Cape Town, South Africa. Participants were classified into four groups according 
to their HIV-1 and TB status, being LTBI or having newly-diagnosed active TB disease (aTB): 
HIV-/LTBI (n = 19), HIV+/LTBI (n = 18), HIV-/aTB (n = 19), and HIV+/aTB (n = 16). The 
clinical characteristics for each group are presented in Table 3.1 and Figure 3.1. LTBI was 
diagnosed based on a positive IFN-γ release assay (QuantiFERON®-TB Gold In-Tube), no 
symptoms of aTB and no detection of Mtb in sputum by GeneXpert. Diagnosis of aTB was 
based on clinical symptoms and positive sputum test. All HIV-infected individuals were 
antiretroviral treatment (ART) naïve and all TB cases were drug sensitive and TB treatment-
naïve at the time of enrolment. This study was approved by the University of Cape Town, 






Table 3.1: Clinical characteristics of the study groups. 
  LTBI Active TB 
  HIV− HIV+ HIV− HIV+ 





                                  
923              
[687-1051] 
547           
[463-626] 
648        
   [593-778] 
153          
[75-207] 












 25 [19-31] 33 [29-38] 31 [26-40] 34 [29-46] 
Sex (F/M) 9/10 16/2 2/17 9/7 







Figure 3.1: Clinical characteristics of the study groups. (A) Pie charts showing sex distribution 
in each clinical group. Summary graph of (B) the age (C) CD4 count in LTBI/HIV− (n=19), 
aTB/HIV- (n=18), LTBI/HIV+ (n=19), and aTB/HIV+ (n=16) and (D) HIV viral load in LTBI and 
aTB individuals. Medians are depicted. Statistical comparisons were performed using a one-way 




3.2.2 Blood collection and whole blood stimulation 
Blood was collected and stimulated as described in Section 2.2.4 in the previous chapter. Mtb 
whole cell lysate (strain H37Rv, 20 μg/ml, BEI Resources) was used to stimulate 0.5 ml of 
heparinized whole blood. 
 
3.2.3 Flow Cytometry 
Cryopreserved cells were thawed, washed and then permeabilized with Perm/Wash buffer (BD 
Biosciences). Cells were incubated at 4°C for 1 h with the following antibodies: CD19 Pacific 
Blue (6D5; Biolegend), CD14 Pacific Blue (M5E2; Biolegend), CD3 BV650 (OKT3; BD 
Biosciences), CD4 PerCP-Cy5.5 (L200; BD Biosciences), CD45RA BV570 (HI100; 
Biolegend), CD27 PE-Cy5 (1A4CD27; Beckman Coulter), CCR7 PECF594 (3D12; BD 
Biosciences), HLA-DR APC-Cy7 (L243; BD Biosciences), KLRG1 PE-vio770 (REA261; 
Miltenyi Biotec), CD26 FITC  (M-A261; BD Biosciences), IFN- Alexa700 (B27; BD 
Biosciences), IL-17 Alexa 647 (N49-653; BD Biosciences), IL-22 PE (22URTI; e-Bioscience). 
Stained cells were acquired on a BD Fortessa and analyzed using FlowJo (v10, TreeStar). A 
positive cytokine response was defined as at least twice the background (i.e. unstimulated cells) 
and more than 10 events. To define the phenotype of cytokines-producing cells, a cutoff of 20 
events was used. These cut-off values were determined empirically and have been shown to be 
reliable in other studies (Strickland et al., 2017; Riou et al., 2017). The gating strategy is 
illustrated in Figure 3.2. 
 
3.2.4 Statistical analysis 











Figure 3.2: Gating strategy. Gating strategy used to determine the phenotype, memory profile and 






3.3.1 Characterization of CD4 Th22 cells in the immune response to Mtb in  
HIV-/LTBI individuals 
A subset of CD4+ T cells that produces the cytokine IL-22 in response to mycobacterial antigen 
stimulation has been described (Scriba et al., 2008). We sought to further characterize Mtb-
specific IL-22 production and define the relative contribution of IL-22 compared to more 
classically measured responses, namely IFN- and IL-17. We first compared the magnitude of 
Mtb-specific IL-22 producing CD4+ T cells to IFN- and IL-17 responses, in whole blood from 
healthy individuals with latent Mtb infection (n = 19; Figure 3.3A). Mtb-specific CD4+ T cell 
responses (producing any of the measured cytokines) were detected in all individuals (median: 
1.34%, interquartile range (IQR): 0.97-2.52) (Figure 3.3B). The highest frequency was 
observed for IFN- responses (median: 0.93%, IQR: 0.40-1.60). Although lower, the 
magnitude of IL-22+ Mtb-specific CD4+ T cells was not significantly different to the IFN- 
response (median: 0.46%, IQR: 0.22-0.96). In contrast, IL-17 producing CD4+ T cells were 
detectable at much lower frequencies (median: 0.06%, IQR: 0.04-0.11), ~16 to ~8 fold lower 
than IFN- (p < 0.0001) and IL-22 (p = 0.0002) responses, respectively (Figure 3.3B). Using 
a Boolean gating strategy, we next assessed all possible cytokine combinations to determine 
the co-expression profile of IFN-, IL-22 and IL-17 in Mtb-specific CD4+ T cells. Figure 3.3C 
shows that the single IFN- response accounted for a median of 60% of the total Mtb response, 
and single IL-22-producing cells contributed a median of 37% to Mtb response. Cytokine co-
expression was marginal, with only a small proportion of IFN-IL-22 co-expressing cells 
observed (median: 3.6%, IQR: 2-6). Only three out of 19 individuals displayed Mtb-specific 
CD4+ T cell responses that produced IL-17 alone that contributed more than 5% to the total 
Mtb response (Figure 3.3C). These results show that IL-22 contributes a substantial portion to 







3.3.2 Mtb-specific Th22 cells exhibit distinct memory and activation profiles compared 
to Th1 and Th17 cells 
To further describe the phenotypic characteristics of Mtb-specific Th22 cells and compare them 
Figure 3.3: Contribution of IFN-, IL-22 and IL-17 to Mtb-specific CD4+ T cell responses in 
LTBI individuals. (A) Representative flow cytometry plots of IFN-, IL-22 and IL-17 production 
after stimulation with MtbL. NS: no stimulation. (B) Summary graph of the frequency of cytokine 
responses. Statistical comparisons were performed using a one-way ANOVA Kruskal-Wallis Dunn's 
multiple comparisons test. ****p < 0.0001. (C) Proportion of different combinations of IFN-, IL-22 
and IL-17 in response to MtbL stimulation. Medians and interquartile ranges are depicted. The pie 




to those of Th1 and Th17 subsets, we compared their memory (CD45RA, CD27 and CCR7), 
activation profile (HLA-DR) and homing potential using Killer cell lectin-like receptor G1 
(KLRG1) and Dipeptidyl peptidase IV (CD26) in heathy individuals with latent Mtb infection. 
During Mtb infection, KLRG1-expressing cells appear to be retained within lung blood 
vasculature, while KLRG1- cells migrate to the lung parenchyma (Sakai et al., 2014). CD26 is 
involved in enzymatic chemokine modification that enhances T cell migration (Iwata et al., 
1999; Ikushima et al., 2002). We focused our analysis on IFN- single producing cells (Th1), 
IL-22 single producing cells (Th22) and IL-17 single producing cells (Th17), since the 
proportion of cytokine co-expressing cells was negligible (Figure 3.3C).  
 
The measurement of CD45RA, CD27 and CCR7 enabled the detection of five distinct memory 
subsets, namely naïve (CD45RA+CD27+CCR7+), central memory (CM: CD45RA-
CD27+CCR7+), transitional memory (TM: CD45RA-CD27+CCR7-), effector memory (EM: 
CD45RA+CD27-CCR7-), and effector cells (Eff: CD45RA-CD27-CCR7-) (Figure 3.4A). The 
memory profile of Mtb-specific CD4+ T cells varied depending on their Th polarization. Th1 
cells were significantly enriched in differentiated EM cells compared to Th22 and Th17 cells 
(median: 50%, 32% and 19%, respectively). The majority of Th22 cells were evenly distributed 
between the CM and EM subset (33 and 32%, respectively). The Th22 subset was also 
characterized by a low proportion of cells exhibiting a TM phenotype compared to the Th1 or 
Th17 subsets (median: 6%, 17%, 18%, respectively; Figure 3.4B).  
 
When assessing the activation profile of Mtb-specific CD4+ Th subsets (Figure 3.5A), we 
observed that Th22 cells were characterized by a significantly lower expression of HLA-DR 
compared to both Th1 and Th17 cells (median 1.1%, compared to 7.3% and 9.3%, respectively; 







Figure 3.4: Comparison of the memory differentiation profiles of Mtb-specific Th1, Th22 and 
Th17 cells in LTBI individuals. (A) Representative overlay plots showing memory subsets in total 
CD4+ T cells (grey), IFN-+ (blue), IL-22+ (red) and IL-17+ (green) cells in response to MtbL. (Naive: 
CD45RA+CD27+CCR7+; central memory (CM): CD45RA-CD27+CCR7+; transitional memory 
(TM): CD45RA-CD27+CCR7-, effector memory (EM): CD45RA-CD27-CCR7- and effector cells 
(Eff): CD45RA+CD27-CCR7-). (B) Summary graph depicting medians and interquartile ranges of the 
memory phenotype of Mtb-specific Th1, Th22 and Th17 cells. Only cytokine responses of more than 
20 events were analyzed. Each dot represents an LTBI individual. Statistical comparisons were 
performed using a one-way ANOVA Kruskal–Wallis test. * p < 0.05, ** p < 0.01, *** p < 0.001, 








and Th17 cells (0.6%, 8.2% and 4.1%; respectively) (Figure 3.5B). In contrast, 50% of Th22 
cells expressed CD26, compared to 34% of Th1 cells and 11% of Th17 cells (p = 0.048 and p 
< 0.0001, respectively) (Figure 3.5B). Overall, these results indicate that Mtb-specific Th22 
cells exhibit distinct memory, activation profiles and homing potential compared to Th1 and 
Th17 cells. 
Figure 3.5: Comparison of the activation profiles of Mtb-specific Th1, Th22 and Th17 cells in 
LTBI individuals. (A) Representative overlay plots showing HLA-DR, KLRG1 and CD26 expression 
in total CD4+ T cells (grey), IFN-+ (blue), IL-22+ (red) and IL-17+ (green) cells in response to MtbL. 
(B) Summary graph depicting medians and interquartile ranges of the expression of HLA-DR, KLRG1 
and CD26 on Mtb-specific Th1, Th22 and Th17 cells. Only cytokine responses of more than 20 events 
were analyzed. Each dot represents an LTBI individual. Statistical comparisons were performed using 




3.3.3 HIV infection and TB disease alters the distribution of Mtb-specific CD4+ Th 
subsets  
To define the impact of HIV infection and TB disease on the distribution of Mtb-specific Th 
subsets, we next compared the magnitude of Th1, Th22 and Th17 cells in 72 participants 
classified into four groups according to their HIV-1 and TB status: HIV-/LTBI (n = 19), 
HIV+/LTBI (n = 18), HIV-/aTB (n = 19), and HIV+/aTB (n = 16). The clinical characteristics 
of each group are summarized in Table 3.1 and Figure 3.1. In participants with LTBI, HIV 
infection led to a significant reduction (median ~3.6 fold) in the frequency of Mtb-specific Th1 
cells (median: 0.23% for and 0.84% for HIV-infected and HIV-uninfected, respectively; p = 
0.026; Figure 3.6A). While not statistically significant, the magnitude of the Mtb-specific 
Th22 response also decreased in HIV-infected participants compared to HIV-uninfected 
subjects (median: 0.18% and 0.45%, respectively). When assessing the effect of TB disease, 
we found that whilst TB disease did not significantly alter the magnitude of Th1 or Th22 
responses in HIV-uninfected individuals, in HIV-infected persons the Mtb-specific Th profile 
was markedly distorted during TB compared to LTBI (Figure 3.6A). The magnitude of Th1 
responses was significantly higher in aTB/HIV+ individuals compared to LTBI/HIV+ 
participants (median: 1.21% vs 0.23%, respectively, p = 0.0005). In contrast, Mtb-specific 
Th22 cells were significantly lower in aTB/HIV+ compared to LTBI/HIV+ (median: 0.08% vs 
0.23%, p < 0.0460). No differences were observed for Mtb-specific Th17 cells in all four 
groups, which were of consistently low magnitude. 
 
To take into account the significant variation in absolute CD4+ T cell counts among 






Figure 3.6: Comparison of the frequency and functional profile of Mtb-responding CD4+ T cells 
in LTBI/HIV− (n=19), aTB/HIV- (n=18), LTBI/HIV+ (n=19), and aTB/HIV+ (n=16). (A) 
Frequency and (B) Absolute number of Th1, Th22 and Th17 responses to MtbL. Red bars represent the 
medians. (C) Distribution of combinations of Mtb-specific cytokine responses as a proportion of the 
total cytokine response. Each section of the pie chart represents median proportions of specific 
combination of cytokines, as indicated by the color at the bottom of the graph. The median and 
interquartile range are indicated by the box and whisker plots. The dotted line indicates 5% of the 
response. Only cytokine responses of more than 20 events were analyzed. Statistical comparisons were 




and compared between each clinical group. As expected, HIV co-infection resulted in reduced 
Mtb-specific Th1 absolute cell numbers regardless of TB status (median: 6.5 vs 1.4 cells/mm3 
in LTBI and 5.4 vs 2.2 cells/mm3 in aTB; Figure 3.6B). A comparable profile was observed 
for Th22 cells, and due to the decreased frequency of Th22 cells in aTB/HIV+ compared to 




circulating Mtb-specific Th22 cells was markedly reduced in aTB/HIV+ individuals (median: 
0.09 cells/mm3 in aTB, compared to 1.02 cells/mm3 in LTBI; Figure 3.6B). Of note, for HIV-
infected individuals, we found no relationship between the frequency of any of the Th cytokine 
responses with absolute CD4 count or HIV viral load, regardless of TB status (Figure S1). 
Next, we examined whether HIV infection and/or active TB alters the relative contribution of 
Th subsets to the total Mtb response. Whilst there were no significant differences in the 
contribution of Th1 and Th22 cells to the Mtb response in LTBI/HIV-, LTBI/HIV+ and 
aTB/HIV- groups (medians for Th1: 60%, 48% and 72%; and medians for Th22: 37%, 37% 
and 22%, respectively), in the aTB/HIV+ group, the Mtb-specific response consisted almost 
exclusively of Th1 cells (>90%), with Th22 cells representing less than 5% of the total Mtb 
response (Figure 3.6C).  
 
 
3.3.4 TB disease and HIV co-infection differentially influence memory and activation 
profiles of Mtb-specific CD4+ Th subsets  
Finally, we performed phenotypic characterization of Mtb-specific CD4+ Th subsets during 
HIV infection and TB disease. Comparing first the memory differentiation phenotype of Th 
subsets, we showed that active bacterial replication, irrespective of HIV co-infection, promotes 
the differentiation of Mtb-specific Th1 cells. The proportion of Th1 cells exhibiting an EM 
phenotype was significantly higher in aTB compare to LTBI (69% vs 50% for HIV-, p = 0.0295 
and 77% vs 45% for HIV+, p = 0.0004; Figure 3.7A). In contrast, no alteration of the memory 
profile of Th22 or Th17 cells was observed in aTB (Figure 3.7B&C). Interestingly, Mtb-
specific CD4+ Th subsets displayed a consistently different memory phenotype in all clinical 
groups, with Th1 cells displaying more differentiated (EM) compared to Th22 and Th17 cells 
(Figure 3.8). In contrast, Th22 and Th17 cells appeared more evenly distributed in the CM and 
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Figure 3.7: Memory phenotypes of Mtb-specific CD4+ T cells in individuals with distinct HIV and 
tuberculosis (TB) disease states. Memory phenotype of (A) Th1, (B) Th22 and (C) Th17 cells in 
LTBI/HIV−, aTB/HIV-, LTBI/HIV+ and aTB/HIV+. Red bars represent the median. Only cytokine 
responses of more than 20 events were analyzed. Statistical comparisons were performed using a one-








We next assessed the effect of HIV infection and aTB on the activation and homing profiles of 
Mtb-specific CD4+ Th subsets. As previously described (Riou et al., 2017), irrespective of 
HIV infection, Mtb-specific Th1 cells in aTB were characterized by significantly higher 
expression of HLA-DR when compared to persons with LTBI (median: 45% vs 7%, 
respectively for HIV-, p = 0.0004 and 60% vs 8% for HIV+, p = 0.0009) (Figure 3.9A).  For 
Th22 cells, the frequency of HLA-DR-expressing cells was significantly higher in HIV-
associated LTBI and aTB (Figure 3.9B). However, this increase in HLA-DR expression in 
Figure 3.8: Comparison of the memory differentiation profiles of Mtb-specific Th1, Th22 
and Th17 cells and the effect of HIV infection and active TB disease. Summary graph of (A) 
LTBI/HIV-, (B) aTB/HIV-, (C) LTBI/HIV+, and (D) aTB/HIV+ individuals. Box and whisker 
plots indicate the median and interquartile range of the phenotype of the different Th subsets. 
Statistical comparisons were performed using a one-way ANOVA Kruskal–Wallis test. * < 0.05 
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Figure 3.9: Activation phenotypes of Mtb-specific Th1, Th22 and Th17 cells in individuals with 
distinct HIV and tuberculosis (TB) disease states. Activation phenotype of (A) Th1, (B) Th22 and 
(C) Th17 cells in LTBI/HIV−, aTB/HIV-, LTBI/HIV+ and aTB/HIV+. Red bars represent the median. 
Only cytokine responses of more than 20 events were analyzed. Statistical comparisons were performed 




Th22 cells observed during HIV infection was most likely due to increased activation in total 
CD4+ T cells caused by HIV infection, as there was a strong correlation between HLA-DR 
expression in Th22 cells and total CD4+ cells (Figure S1). One interpretation of Th22 cells 
not expressing HLA-DR would be that Th22 responses are not specific for Mtb, however, TCR 
blocking data from Chapter 2 demonstrate that these responses are indeed specific. Of note, 
there were lower frequencies of Th22 cells expressing HLA-DR compared to both Th1 and 
Th17 cells in all clinical groups (Figure 3.10). Similar to Th22 cells, no differences were 
observed in HLA-DR expression in Th17 cells during aTB (Figure 3.9C).  
 
We did not observe any differences in the homing potential of Mtb-specific CD4+ Th subsets 
based on KLRG1 expression during HIV infection and/or TB disease (Figure 3.9A, B&C). In 
contrast, CD26 expression on Th1 cells was higher in aTB/HIV+ (median: 55%) compared to 
aTB/HIV- (median: 34%, p = 0.0112), LTBI/HIV+ (median: 34%, p = 0.0083), and LTBI/HIV- 
(median: 34%, p = 0.0037) (Figure 3.9A). On Th22 cells, expression of CD26 was lower in 
aTB/HIV- individuals compared to LTBI/HIV- (median: 41% and 51%, respectively; p = 
0.0373) (Figure 3.9B). We did not observe any differences in homing potential for Th17 
responses (Figure 3.9C), which is likely due to the infrequent Th17 responses detected. CD4+ 
T helper cells also displayed differences in CD26 and KLRG1 expression during aTB and HIV 
infection (Figure 3.10). 
 
These data confirm that active Mtb replication causes memory differentiation of Mtb-specific 
Th1 cells. Consequently, Th1 cells are highly activated during active TB, irrespective of HIV 
infection. In contrast, TB disease does not alter memory or activation phenotype profile of 
Mtb-specific Th22 cells but may affect their homing potential. Indicating that TB differentially 













Figure 3.10: Comparison of the activation and homing profiles of Mtb-specific Th1, Th22 and 
Th17 cells and the effect of HIV infection and active TB disease. Summary graph in (A) 
LTBI/HIV-, (B) aTB/HIV-, (C) LTBI/HIV+, and (D) aTB/HIV+ individuals. Box and whisker plots 
indicate the median and interquartile range of the phenotype of the different Th subsets. Statistical 
comparisons were performed using a one-way ANOVA Kruskal–Wallis test. * < 0.05 ** < 0.01, *** 





The importance of CD4+ Th1 (IFN-) and Th17 (IL-17) responses in protective immunity to 
Mtb is well established (Jasenosky et al., 2015; Shen and Chen, 2018). The emerging role of 
IL-22 and Th22 cells in TB immunity is less well studied, and we sought to address this 
knowledge gap. To better understand the contribution of Th22 cells to Mtb immune responses, 
we examined the dynamics of this subset in TB disease, and the effect of HIV co-infection, by 
comparing the magnitude, differentiation and activation profiles of CD4+ T cells producing 
IFN-, IL-22 and IL-17. We extend our previous observations from latent Mtb infection, where 
we demonstrated that IL-22 contributes substantially to the total CD4+ T cell response to Mtb, 
to show for the first time that Th22 cells displayed distinct memory and activation profiles 
compared to Th1 and Th17 cells, and that Mtb-specific Th22 were severely depleted in the 
context of HIV infection and TB disease. 
 
Recently, we reported that Th22 cells constituted up to 50% of mycobacterial responses in 
Mtb-exposed individuals (Bunjun et al., submitted), in line with previous studies (Scriba et al., 
2008).  In the current study, we confirmed that IL-22 contributes a substantial portion to Mtb 
immune response, with the magnitude of Th22 responses to Mtb at a median of 37% of the 
total Mtb response measured, with Th1 cells contributing 60% and Th17 cells less than 5% to 
the response. These data demonstrate that Th22 cells make up a large portion of the immune 
responses to TB and it remains to be shown whether Th22 cells play a role in TB immunity. 
Indeed, IL-22 was found to play a protective role against hypervirulent Mtb clinical strain 
HN878 (Treerat et al., 2017). This and other studies also demonstrated that IL-22 receptors are 
expressed on macrophages within the granuloma, and IL-22 was shown to inhibit Mtb growth 
directly through induction of TNF- to activate macrophages or by enhancing phagolysosomal 




2012; Treerat et al., 2017). IL-22 also acts on lung epithelial cells to induce antimicrobial 
proteins or recruits other immune cells (Liang et al., 2006; Treerat et al., 2017). Further studies 
are required to elucidate how IL-22 contributes to Mtb control.  
  
IL-22 was thought to be a Th17 cytokine due to co-expression with IL-17 in mouse studies and 
shared function between the two cytokines (Liang et al., 2006). Consistent with previous 
studies, our co-expression profile of IFN-, IL-22 and IL-17 confirmed that IL-22 is mostly 
produced independently of IFN- and IL-17 (Duhen et al., 2009; Trifari et al., 2009).  This 
implies that IFN-, IL-22 and IL-17 might play different roles during an immune response 
(Ouyang et al., 2008). Indeed, IL-22 was required for Mtb control at the chronic stage of Mtb 
infection, while IL-17 was important in the acute stage of Mtb infection in mice (Gopal et al., 
2014; Treerat et al., 2017). Although IL-22 and IL-17 have some overlapping functions, such 
as induction of antimicrobial peptides, regulating chemokine expression for immune cell 
recruitment to sites of infection and promoting tissue proliferation, regeneration, and healing 
(Liang et al., 2006; Gopal et al., 2014; Sabat et al., 2014; Treerat et al., 2017), IL-22 may also 
mediate mycobacterial control by inducing TNF-α production to activate macrophages 
(Dhiman et al., 2012; Treerat et al., 2017), a function that has previously been associated with 
IFN- (Flynn et al., 1993).  
 
Consistent with our recent findings (Bunjun et al., submitted), HIV infection resulted in a lower 
frequency of Th1 and Th22 cells in Mtb-exposed individuals, albeit non-significantly in the 
present study for Th22 cells. The majority of Th22 cells express CCR6 (Duhen et al., 2009) 
and CD4+ CCR6+ cells have been linked to increased permissiveness to HIV infection 
(Gosselin et al., 2010; Monteiro et al., 2011; Alvarez et al., 2013), are enriched in HIV DNA 




(Planas et al., 2017). Indeed, CD4+CCR6+ cells have been shown to express high levels of 
HIV co-receptors CCR5 and CXCR4 important for viral entry, and integrin 47 which has 
been associated with increased HIV susceptibility (El Hed et al., 2010; Monteiro et al., 2011; 
Alvarez et al., 2013; Sivro et al., 2018). Furthermore, CCR6+ cells lack CCR5 ligands which 
have been shown to induce autocrine protection against HIV (El Hed et al., 2010; Alvarez et 
al., 2013). 
 
The frequency of mycobacteria-specific Th1 and Th22 cells has also been shown to be lower 
in individuals with TB compared to healthy individuals (Scriba et al., 2008). Here, we observed 
no differences in Mtb-specific Th1 response between individuals with latent TB infection and 
TB patients. However, Mtb-specific Th22 responses were 50% lower in individuals with TB 
compared to Mtb exposed individuals. Since IL-22-producing cells express CCR6, this may 
signal that during active TB disease these cells migrate to the lungs from the circulation 
(Annunziato et al., 2007; Acosta-Rodriguez et al., 2007). Soluble IL-22 is elevated at the site 
of infection during pulmonary and extra-pulmonary TB (Scriba et al., 2008; Matthews et al., 
2011a) and IL-22 producing cells have been detected in the lungs and granulomas of rhesus 
monkeys with TB (Qiu et al., 2008; Yao et al., 2010). Of note, isoniazid preventive therapy 
(IPT) resulted in an increase in frequencies of mycobacteria-specific IL-22 producing CD4+ T 
cells in blood (Suliman, Geldenhuys, John L Johnson, et al., 2016), suggesting a restoration in 
blood after sterilization of bacteria at the site of infection. Zhang et al. reported an increase in 
Mtb-specific soluble IL-22 in blood of TB patients after TB treatment, which was associated 
with a decrease in the frequencies of regulatory B cells (CD19+CD5+CD1d+) (Zhang et al., 
2014), suggesting that reduction of antigen load in the site by anti-TB drugs leads to restored 
IL-22 responses in blood. A major, novel finding from our study was that Mtb-specific Th22 




Based on the reasons stated above, we speculate that in addition to depletion of Mtb-specific 
CD4+ Th22 cells as a result of HIV infection, that during active TB, Mtb-specific Th22 cells 
migrate out of blood into the lungs, resulting in Th22 cells being diminished in the blood during 
HIV-TB co-infection. 
 
We confirmed that Th1 cells mostly consist of effector memory subset (50%) while Th22 cells 
displayed similar distribution between central (33%) and effector (32%) memory subsets. By 
characterizing memory subsets using CD45RA, CCR7 and CD27 expression, we were able to 
provide a more detailed definition than previously reported (Bunjun et al., submitted). Central 
memory cells home to secondary lymphoid organs and have delayed effector function, while 
effector memory subset possess an immediate effector function (Sallusto et al., 1999). This 
suggests that Th22 cells are potentially longer lived with the ability to migrate to the site of 
infection but may possess less rapid effector function compared to Th1 cells. We also observed 
differences in the activation profiles between Th22, Th1 and Th17 cells. Only 1% of Th22 cells 
expressed HLA-DR, which was significantly lower than Th1 cells (7%; p = 0.0006) and Th17 
cells (9%; p = 0.0026). This could suggest that other activation markers (e.g. CD25, CD69 or 
CD26) may be required to detect the activation status of Th22 cells (Rea, McNerlan and 
Alexander, 1999).  Indeed, we observed CD69 and CD25 upregulation on IL-22-producing 
cells upon Mtb stimulation (Wendoh, Keeton, Burgers, unpublished). Th22 cells did not 
demonstrate upregulation of HLA-DR even in TB disease, while Th1 cells expressed high 
levels of HLA-DR in the context of TB disease, irrespective of HIV status (Adekambi et al., 
2015; Riou et al., 2017). Indeed, the increased level of activation on Th22 cells observed during 
HIV infection, unlike Th1, merely mirrored the background activation in due by HIV, 





In conclusion, our study builds on previous work that Th22 cells contribute substantially to the 
immune response to Mtb during both infection and disease, and that these cells are reduced in 
blood during HIV co-infection.  We hypothesise that Th22 cells can migrate to the lungs for 
an effective response to provide protection against TB. Further investigation of the role of Th22 
cells in TB immunity is warranted, to generate insights that could contribute to the development 
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The importance of CD4+ T cells in protective tuberculosis (TB) immunity has been extensively 
studied and it is widely accepted that these cells play a critical role in Mycobacterium 
tuberculosis (Mtb) control (Leveton et al., 1989; Selwyn et al., 1989; Caruso et al., 1999; Lawn 
et al., 2002; Lin et al., 2012). However, the role of CD8+ T cells in controlling Mtb is still 
controversial.  
 
Since Mtb is a facultative intracellular pathogen, infection typically leads to processing via 
vacuolar pathways and MHC II presentation of Mtb antigens to CD4+ T cells. However, 
secreted Mtb antigens can be processed by cytosolic pathways and presented by MHC class I 
molecules to elicit Mtb-specific CD8+ responses (Lewinsohn et al., 2006). CD8+ T cells 
specific for ESAT-6/CFP-10 have been detected in TB patients and Mtb-exposed individuals 
(Lalvani et al., 1998). Upon activation, CD8+ T cells can produce IL-2, IFN-γ, and TNF-α, 
which may contribute to effective immunity against Mtb (Silva et al., 2014). 
 
In mouse models, some studies have shown that mice deficient in CD8+ T cells had a higher 
Mtb burden and a slight decrease in survival (Sousa et al., 2000; van Pinxteren et al., 2000; 
Badri et al., 2001; Mogues et al., 2001). In contrast, other murine studies have reported that 
depletion of CD8+ T cells does not affect Mtb bacterial load or survival (Leveton et al., 1989; 
Flory et al., 1992). In non-human primate (NHP) models, depleting CD8+ T cells in bacille 
Calmette-Guérin (BCG)-vaccinated rhesus macaques resulted in higher levels of bacteria in 
bronchoalveolar lavage (BAL) fluid and lung lobes after pulmonary Mtb infection (Chen et al., 
2009). Moreover, a loss of immune control of TB following re-infection was evident in CD8-
depleted rhesus macaques that had previously been cured from Mtb (Chen et al., 2009), 




that unlike CD4+ responses, Mtb-specific CD8+ T cells may be more important during the 
latent phase of Mtb infection than acute phase of infection (van Pinxteren et al., 2000; Mogues 
et al., 2001). This was demonstrated in mouse models, where in vivo depletion of CD8+ T cells 
resulted in higher bacterial burden in the lung during the chronic stage of Mtb infection, while 
CD4+ T cell depletion resulted in higher bacterial burden in the lung during the acute phase of 
Mtb infection (van Pinxteren et al., 2000; Mogues et al., 2001).  
In humans, the anti-TNF therapeutic infliximab used for treatment of rheumatoid arthritis (RA) 
has been shown to promote TB progression, in part by depleting a subset of effector memory 
CD8+ T cells that contributes to the killing of Mtb (Bruns et al., 2009). In a study by Yang et 
al., CD8+ T cell lines that recognized the Mtb immunodominant epitope TB10.4 did not 
recognize Mtb-infected macrophages nor inhibit the growth of Mtb (Yang et al., 2018). 
However, TB10.4-specific CD8+ T cells were reported to mediate protection against Mtb 
through IFN- release and transporters associated with antigen processing (TAP)-dependent 
antigen presentation (Nunes-Alves et al., 2015).  
 
In vitro, Mtb-specific CD8+ T cells can aid in killing Mtb-infected cells by secreting IFN-γ 
and TNF-α cytokines (Stenger et al., 1997; Lalvani et al., 1998; Cho et al., 2000), or producing 
cytotoxic molecules such as perforin and granulysin (Lalvani et al., 1998; Cho et al., 2000). 
Using Mtb-specific T cell clones, Lewinsohn and colleagues found that CD8+ T cells 
preferentially recognize heavily Mtb-infected cells, suggesting that CD8+ T cells may also play 
a role of surveillance of cells with higher numbers of intracellular bacilli (Lewinsohn et al., 
2003).  
HIV infection has been shown to impair CD4+ immunity to TB by progressive depletion of 
CD4+ T cell numbers (Sonnenberg et al., 2005), preferentially depleting Mtb-specific CD4+ 




(Riou et al., 2016). HIV infection also impairs the CD8+ compartment, skewing the memory 
differentiation profile of CD8+ T cells, with the accumulation of pre-terminally differentiated 
CD45RA-CCR7- cells instead of terminally differentiated CD45RA+CCR7- cells (Champagne 
et al., 2001). This pre-terminally differentiated memory phenotype is associated with CD8+ T 
cells expressing low levels of perforin and possessing impaired cytolytic activity in HIV 
disease (Appay et al., 2000; Andersson et al., 2007). Thus, HIV is thought to induce loss of 
cytolytic effector molecules in pathogen-specific cytotoxic CD8+ T cells (CTLs).  
 
The impact of HIV-1 co-infection on Mtb-specific CD8+ T cells is relatively understudied. 
One study with participants with latent TB showed that ESAT-6/CFP-10-specific CD8+ T cells 
from HIV-coinfected people exhibited decreased expression of the degranulation marker 
CD107a and impaired proliferative capacity (Kalokhe et al., 2015). Thus, as for CD4+, it is 
plausible that HIV promotes premature exhaustion of Mtb-specific CD8+ T cells, affecting 
their functional capacity and/or survival potential.  
 
In this study, we sought to define the magnitude and phenotypic profile of Mtb-specific CD8+ 
T cell responses, compare them to CD4+ responses and investigate the impact of HIV infection 









4.2 Material and methods 
4.2.1 Study participants  
Blood samples were collected from 70 participants divided in four groups according to their 
HIV-1 and TB status: HIV-/LTBI (n = 19), HIV+/LTBI (n = 17), HIV-/aTB (n = 19), and 
HIV+/aTB (n = 15). Detailed clinical characteristics of study participants are described in 
Section 3.2.1, Table 3.1 and Figure 3.1.  
 
4.2.2 Blood collection and whole blood stimulation 
Blood was collected and stimulated as described in Section 2.2.4. Mtb-specific peptide pool 
[(4 μg/ml), consisting of 17 and 16 peptides covering the entire ESAT-6 (early secretory 
antigenic target) and CFP-10 (culture filtrate protein) was used to stimulate 0.5 ml of 
heparinized whole blood.  
 
4.2.3 Flow Cytometry 
Cryopreserved cells were thawed, washed and then permeabilized with Perm Wash buffer (BD 
Biosciences). Cells were incubated at 4 °C for 1 h with the following antibodies: CD19 Pacific 
Blue (6D5; Biolegend), CD14 Pacific Blue (M5E2; Biolegend), CD3 BV650 (OKT3; BD 
Biosciences), CD4 PerCP-Cy5.5 (L200; BD Biosciences), CD8 BV510 (RPA-T8; Biolegend), 
CD45RA BV570 (HI100; Biolegend), CD27 PE-Cy5 (1A4CD27; Beckman Coulter), CCR7 
PECF594 (3D12; BD Biosciences), KLRG1 PE-vio770 (REA261; Miltenyi Biotec), HLA-DR 
APC-Cy7 (L243; BD Biosciences), IFN- Alexa700 (B27; BD Bioscience), TNF- BV785 
(MAb11; Biolegend), IL-17 Alexa 647 (N49-653; BD Biosciences), IL-22 PE (22URTI; e-
Bioscience). Stained cells were acquired on a BD Fortessa and analyzed using FlowJo (v10, 




unstimulated cells) and more than 10 events. To define the phenotype of cytokines-producing 
cells, a cutoff of 20 events was used. The gating strategy is illustrated in Figure 4.1. 
 
4.2.4 Statistical analysis 
Statistical tests were performed as described in Section 2.2.6. 
 
4.3 Results 
4.3.1 The profile of Mtb-specific CD8+ and CD4+ T cell responses during TB disease 
and/or HIV infection 
To define the contribution of CD8+ T cells to Mtb immune responses, we first measured and 
compared the magnitude of cytokine (IFN-, TNF-, IL-22 and IL-17)-producing cells in the 
CD4+ and CD8+ compartment. Blood was stimulated with ESAT-6/CFP-10 peptide pool in 
70 participants divided into four groups according to their HIV-1 and TB status: HIV-/LTBI 
(n = 19), HIV+/LTBI (n = 17), HIV-/aTB (n = 19), and HIV+/aTB (n = 15) (described in Table 
3.1, Figure 3.1 in the previous Chapter). As negligible amount of IL-22 and IL-17 were 
detected in all groups from both CD4+ and CD8+ T cells in response to peptide pool 
stimulation (Figure S2), we focused our analysis on Th1 cytokines (i.e. IFN- and TNF-). 
Figure 4.1 shows representative flow cytometry plots of IFN- and TNF- production from 
one donor in each clinical group. Responders were defined as individuals producing any 
combination of IFN- and/or TNF-.  
 
We first investigated the impact of HIV infection and TB disease on the proportion of 
individuals with detectable Mtb peptide-specific CD4+ and CD8+ T cells (Figure 4.2B). In 
LTBI individuals, T cell response to Mtb peptides were more prevalent in the CD4+ 





26%; p = 0.0487 in HIV-uninfected individuals and 82% vs 24%, p = 0.0006 in HIV-infected 
individuals; respectively). There were no significant differences in the proportion of 
individuals with detectable Mtb peptide-specific CD4+ T cells between HIV-/LTBI, 
HIV+/LTBI, HIV-/aTB, and HIV+/aTB groups (58%, 82%, 78%, and 80%; respectively). 
 
Conversely, the proportion of individuals exhibiting an Mtb-specific CD8+ response was 
elevated in active TB compared to LTBI in both HIV-uninfected and HIV-infected persons 
(60% vs 24% for HIV+, p = 0.036; and 50% vs 26% for HIV-; p = 0.14). It is not surprising 
Figure 4.1: Gating strategy. Gating strategy used to determine the phenotype, memory profile and 




that the effect observed in the magnitude of CD4 ESAT6/CFP10 response in LTBI/HIV- vs 
LTBI/HIV+ is less than that observed in Figure 3.6 where Mtb lysate was used, as this is 
consistent with a previous study (Riou et al., 2017). These data are in accordance with 
previously published data (Rozot et al., 2013; Amelio et al., 2018). 
Next, we compared the magnitude of IFN- and/or TNF- responses to Mtb peptides in the 
CD4+ and CD8+ compartment in individuals with detectable responses and defined the effect 
of HIV infection and active TB on these responses (Figure 4.2C). While the frequency of Mtb-
specific CD4+ and CD8+ responses were comparable in the HIV-/LTBI, HIV+/LTBI and HIV-
/aTB groups, the magnitude of CD4+ responses was significantly higher compared to CD8+ 
responses in the HIV+/aTB group (medians: 0.83% and 0.14%; p = 0.0009, respectively). 
Although active TB resulted in a higher proportion of CD8 responders in HIV-infected 
individuals, no differences were observed in the frequency of CD8+ responses between any of 
the disease groups (medians: HIV-/LTBI = 0.076%, HIV+/LTBI = 0.082%, HIV-/aTB = 
0.282%, and HIV+/aTB = 0.143%). However, in HIV-infected individuals, TB disease 
significantly altered cytokine co-expression of Mtb-specific CD8+ T cells (p = 0.007, Figure 
4.2D). Regarding CD4+ responses, our results show that whilst aTB did not significantly alter 
the magnitude of CD4+ responses in HIV-uninfected individuals (medians: 0.29% for aTB and 
0.22% for LTBI), in HIV-infected persons with aTB the Mtb peptide-specific CD4+ responses 
were significantly higher compared to LTBI (medians: 0.73% and 0.14%; p = 0.006, 
respectively). These results are consistent with the CD4+ Th1 response profile observed upon 




Figure 4.2 on the next page: Comparison of the frequency of Mtb peptide-specific CD4+ and CD8+ 
T cells in LTBI/HIV− (n=19), aTB/HIV- (n=18), LTBI/HIV+ (n=19), and aTB/HIV+ (n=15). (A) 
Representative flow cytometry plots showing IFN- and TNF- production by CD4+ and CD8+ T cells 
in response to stimulation with ESAT-6/CFP-10 peptide pool. (B) Proportions of individuals with 
detectable Mtb-specific CD4+ and CD8+ T cells. (C) Frequency of Mtb-specific CD4+ and CD8+ T cells 
producing any combination of IFN- and TNF- in four clinical groups. Only individuals with detectable 
responses are shown. The bars represent the median. (D) Pie charts showing different combinations of 
IFN- and TNF-. Medians are depicted. Statistical comparisons were performed using chi-square test 
(B), one-way ANOVA Kruskal–Wallis test (C) and permutation test using the SPICE software (D). * p 










4.3.2 The effect of HIV infection and TB disease on Mtb-specific CD4+ and     CD8+ T 
cell memory profile 
We next characterized and compared the memory profile of Mtb peptide-specific CD4+ and 
CD8+ responses during HIV infection and aTB disease (Figure 4.3). As for Mtb lysate-specific 
Th1 responses (presented in Section 3.3.3, Figure 3.7), we found that during aTB, Mtb 
peptide-specific CD4+ T cells displayed a more differentiated phenotype (EM) compared to 
HIV-infected individuals with LTBI, but not HIV-uninfected individuals (medians: 32% vs 
68% for HIV+, p = 0.025 and 48% vs 67% for HIV-, p = ns) (Figure 4.3B). Concomitantly, a 
lower proportion of CD4+ T cell responses with a central memory phenotype was observed in 
aTB compared to LTBI in HIV-infected individuals, but not HIV-uninfected individuals 
(medians: and 36% vs 9% for HIV+, p = 0.025 and 15% vs 15% for HIV-, p = ns) (Figure 
4.3B). Although we did not observe any significant changes in the memory phenotype of Mtb 
peptide-specific CD8+ T cells during HIV infection and/or TB disease, there was a trend 
towards an increased proportion of transitional memory (TM) (CD45RA-CD27+CCR7+) cells 
in HIV-infected TB patients compared to LTBI individuals (medians: 50% vs 17%, 
respectively; p = 0.058) (Figure 4.3B). 
 
In LTBI individuals, Mtb-specific CD8+ T cells displayed a more differentiated memory 
phenotype compared to Mtb-specific CD4+ T cells, where Mtb-specific CD8+ T cells were 
enriched in cells with an effector phenotype compared to Mtb peptide-specific CD4+ T cells 
(Figure 4.3B). This was also observed in the entire CD8+ compartment compared to the CD4+ 
compartment in all clinical groups (Figure 4.4) indicating that CD8+ T cells are inherently 
different to CD4+ T cells in their memory differentiation profiles. These results suggest that 
active Mtb replication leads to the memory differentiation of Mtb-specific CD4+ T cells and 




Figure 4.3: Comparison of the memory differentiation profile of Mtb peptide-specific CD4+ and CD8+ cells in individuals with distinct HIV and TB 
disease states. (A) Representative overlay plots showing memory subsets in total CD4+ and CD8+ T cells (grey), IFN-+ and/or TNF-+ cells (brown) in 
response to response to ESAT-6/CFP-10 peptides pool. (Naive: CD45RA+CD27+CCR7+; central memory (CM): CD45RA-CD27+CCR7+; transitional 
memory (TM): CD45RA-CD27+CCR7-, effector memory (EM): CD45RA-CD27-CCR7-and effector cells (Eff): CD45RA+CD27-CCR7-). (B) Summary 







4.3.3 The effect of HIV infection and TB disease on Mtb-specific CD4+ and CD8+ T 
cells activation profile 
Lastly, we assessed the activation profile of Mtb peptide-specific CD4+ and CD8+ responses 
during HIV infection and aTB disease using HLA-DR and KLRG1 (Figure 4.5). As previously 
described in Figure 3.8 in the previous Chapter, Mtb peptide-specific CD4+ T cells were 
characterized by significantly higher expression of HLA-DR in aTB compared to LTBI 
(median: 36% vs 17%, for HIV-, p = 0.009 and 50% vs 17% for HIV+, p = 0.003, respectively). 
While not reaching significance because of low number of CD8 responders in LTBI groups, 
there was a higher frequency of HLA-DR-expressing Mtb peptide-specific CD8+ T cells in 
active TB compared to LTBI (median: 41% vs 13%, for HIV- , p = 0.794 and 73% vs 16% for 
HIV+, p = 0.201, respectively), with HLA-DR frequencies being comparable between Mtb 
peptide-specific CD8+ T and Mtb peptide-specific CD4+ T cells in all clinical groups (Figure 
4.5B). In fact, the activation profile of Mtb peptide-specific CD8+ T cells mirrored that 
Figure 4.4: Comparison of the memory differentiation profile of total CD4+ and CD8+ T cells in 
individuals with distinct HIV and TB disease states. Medians are depicted. Statistical comparisons 





observed in Mtb peptide-specific CD4+ T cells, as illustrated by the positive linear relationship 
(r = 0.62; p = 0.003) (Figure 4.5C). Interestingly, HLA-DR expression was also comparable 
between total CD4+ or CD8+ in all groups, and TB disease did not distort the activation 
phenotype of total CD4+ and CD8+ T cells (Figure 4.6A), suggesting that elevated activation 
observed during aTB is restricted to CD4+ and CD8+ T cells targeting Mtb peptides and most 
probably driven by pathogen replication.  
 
HIV infection and/or TB disease did not induce any changes in KLRG1 expression on both 
Mtb peptide-specific CD4+ T cells and Mtb peptide-specific CD8+ T cells (Figure 4.5D). 
However, Mtb peptide-specific CD8+ T cells were characterized by elevated KLRG1 
expression compared to Mtb peptide-specific CD4+ T cells in all groups (medians: 50% vs 6% 
for LTBI/HIV-, p = 0.19 and 58% vs 5% for LTBI/HIV+, p = 0.09; 66% vs 6% for aTB/HIV, 
p = 0.003 and 73% vs 5% for aTB/HIV+, p = 0.021; respectively) (Figure 4.5D). Nevertheless, 
there was a positive association of KLRG1 expression between Mtb-specific CD8+ T cells and 
Mtb-specific CD4+ T cells (r = 0.56; p = 0.009) (Figure 4.5E). Similarly, total CD8+ T cells 
expressed more KLRG1 compared to CD4+ T cells in all disease groups (medians: 60% vs 
11% for LTBI/HIV-, p < 0.0001, 72% vs 13% for LTBI/HIV+, p < 0.0001, 57% vs 10% for 
aTB/HIV-, p < 0.0001 and 58% vs 12% for aTB/HIV+, p = 0.006; respectively) (Figure 4.6B).  
 
Interestingly, there was a positive association of HLA-DR and KLRG1 expression between 
Mtb-specific CD4+ T cells and total CD4+ T cells (r = 0.42; p = 0.006 for HLA-DR and r = 
0.39; p = 0.008 for KLRG; Figure 4.7). Similarly, although not reaching significance, there 
was a positive correlation between Mtb-specific CD4+ T cells and total CD8+ T cells 








Figure 4.5: Comparison of the activation phenotype of Mtb-specific CD4+ and CD8+ cells in 
individuals with distinct HIV and TB disease states. (A) Representative overlay plots showing 
HLA-DR and KLRG1 expression in total CD4+ and CD8+ T cells (grey), IFN-+ and/or TNF-+ 
cells (brown) in response to ESAT-6/CFP-10 peptides pool. (B) Summary graph. Medians are 
depicted. Statistical comparisons were performed using a one-way ANOVA Kruskal–Wallis test. * p 
< 0.05, ** p < 0.01. (C) The relationship between Mtb peptide-specific CD4+ and CD8+ T cells 
expressing HLA-DR and KLRG1. Each dot represents an individual. Statistical analyses were 





In summary, we show that the presence of replicating pathogen (Mtb) during TB disease 
leads to activation of Mtb peptide-specific CD4+ T cells. Further assessment of CD8+ T 
cell activation is needed, and the cytotoxic potential of these CD8+ T cells is required to 
elucidate the role of CD8+ T cells in TB immunity. 
Figure 4.6: Comparison of HLA-DR and KLRG1 expression on total CD4+ and CD8+ T cells 
in individuals with distinct HIV and TB disease states. Medians are depicted. Statistical 











Figure 4.7: The relationship between Mtb peptide-specific CD4+ or CD8+ T cell activation with 
total CD4+ or CD8+ T cell activation profile. The relationship between Mtb peptide-specific CD4 or 
CD8 T cells with total CD4+ or CD8+ T cells expressing (A) HLA-DR and (B) KLRG1. Each dot 






CD4+ T cells and CD8+ T cells produce Th1 cytokines (IFN- and TNF-) which can activate 
macrophages and inhibit Mtb growth (MacMicking et al., 2003). HIV infection has been shown 
to impair Mtb-specific CD4+ responses, enhancing the risk of progression from LTBI to active 
TB (Day et al., 2014; Kalokhe et al., 2015; Amelio et al., 2018). However, relatively little is 
known about the effect of HIV on Mtb-specific CD8+ T cells. Therefore, we investigated the 
impact of HIV infection on the memory and activation profile and functional capacities of Mtb-
specific CD8+ T cells during LTBI and TB disease and compared their phenotypic profile to 
Mtb-specific CD4+ responses.  
 
Consistent with previous studies, we detected CD8+ responses following stimulation of blood 
with ESAT-6/CFP-10 peptide pool (Rozot et al., 2013; Amelio et al., 2018). Mtb peptide-
specific CD8+ T cells were more frequently detected in individuals with active TB disease 
compared to latently infected individuals (60% vs 24% for HIV+, p = 0.036 and 50% vs 26% 
for HIV-; p = 0.14), in agreement previously reports (Rozot et al., 2013; Amelio et al., 2018). 
Reasons for this observation could be that CD8+ T cells preferentially recognize heavily Mtb-
infected cells (Lewinsohn et al., 2003), providing evidence that CD8+ T cells may play a role 
of surveillance of cells with higher numbers of intracellular bacteria. Indeed, the frequency of 
Mtb-specific CD8+ T cells is associated with Mtb bacterial burden in both humans and mice 
(Billeskov et al., 2007; Day et al., 2011). Furthermore, reduction of Mtb load by anti-TB 
treatment has been shown to result in a decrease in Mtb-specific CD8 responses (Nyendak et 
al., 2013; Day et al., 2014). 
 
The CD8+ responses detected in this study are most likely an underestimate of the actual 




we used 15 amino acid ESAT-6/CFP-10 peptides which are not entirely optimal for the 
detection of CD8+ responses (usually 9 amino acid peptides are used for CD8+ T cells), and 
we only tested two proteins, while other Mtb proteins could be more immunogenic and detect 
a greater range of CD8+ responses (Rakshit et al., 2017). Since Mtb lysate is a mixture of all 
the proteins, lipids and carbohydrates present in the cell; thus, Mtb lysate stimulates innate 
cells, conventional and non-conventional T cells. Therefore, given that other non-conventional 
cells express CD8 as shown in Figure 2.8C, we would not be able differentiate between 
cytokines produced by CD8+ T cells and other non-conventional cells as we did not include 
their markers. Thus, we examined responses to Mtb peptide antigens. 
 
In LTBI, both bulk CD8+ memory cells targeting Mtb reflect total memory CD8+ T cells in 
that they are maintained in a more differentiated memory profile (effector memory and effector 
cells) and express elevated KLRG1 compare to CD4+ cells. These observations are consistent 
with studies that have shown that KLRG1 expression on T cells is associated with an increased 
effector function in Mtb infection (Chattopadhyay et al., 2009; Hu et al., 2018). It is also 
consistent with the hypothesis that KLRG1 expression is dependent on cell division, as CD8+ 
T cells proliferate more vigorously after antigen challenge than CD4+ T cells (Foulds et al., 
2002; Voehringer et al,, 2002). While the expression of KLRG1 and having a specific effector 
memory (EM) phenotype for CD4+ T cells is considered detrimental for immunity against TB 
(Wang et al., 2010; Lindenstrom et al., 2013; Sakai et al., 2014), effector memory subsets of 
CD8+ T cells were reported to have a high cytolytic potential which correlates with another 
senescence maker CD57 (Sallusto et al., 1999; Takata and Takiguchi, 2006; Chattopadhyay et 
al., 2009). Thus, our results highlight differences in Mtb-specific CD4+ and CD8+ T cells 





HIV infection has been shown to impair degranulation and proliferative capacity of Mtb-
specific CD8+ T cells (Kalokhe et al., 2015). Due to low number of individuals in our cohort 
and a low proportion of Mtb-specific CD8+ T cells in individuals with LTBI, we were unable 
to identify statistically significant defects caused by HIV infection on Mtb peptide-specific 
CD8+ T cells. However, we observed a trend towards an increase in proportion of Mtb-specific 
CD8+ T cells displaying a transitional memory profile (TM) (CD45RA-CD27+CCR7+) during 
aTB compared to LTBI, in HIV-infected individuals. this supports the hypothesis that TB co-
infection alters CD8+ T-cell differentiation. Indeed, TB disease has been shown to impair 
differentiation of Mtb-specific CD8+ T cells, as individuals with active TB are characterized 
by a higher proportion of CD45RA−CCR7− compared to LTBI individuals which display a 
fully differentiated memory profile (CD45RA+CCR7−) (Caccamo et al., 2009; Rozot et al., 
2013; Suarez et al., 2015). This deficient CD8+ T-cell memory differentiation may result from 
premature exhaustion of CD8+ T cells caused by chronic activation during HIV infection and 
TB disease (Breton et al., 2013; Amelio et al., 2018). It is not clear whether HIV infection 
directly influences memory maturation of Mtb-specific CD8+ T cells or indirectly by impairing 
CD4+ T cells, which have been implicated in CD8+ T cell development and maturity 
(Matloubian et al., 1994; Serbina et al., 2000; Sun et al., 2004). 
 
While CD8+ T cells are thought to be less important than CD4+ T cells in the control of Mtb, 
multiple lines of evidence do indeed support a role for CD8+ T cells in protective immunity. 
Like CD4+ T cells, CD8+ T cells have been shown to produce cytokines (IFN-, TNF-a and 
IL-2) that play vital roles during Mtb infection (Kamath et al., 2006; Gideon et al., 2015). 
Furthermore, CD8+ T cells have the potential to kill target cells through the release of perforin, 
granzymes, and granulysin (Serbina et al., 2000; Andersson et al., 2007). Indeed, in vitro 




macrophages through the release of cytotoxic granules (granulysin and perforin) (Stenger et 
al., 1997, 1998). Moreover, peripheral CD8+ T cells cell lines specific for Mtb peptides were 
able to recognize and lyse Mtb-infected macrophages in vitro (Cho et al., 2000). In mouse 
models, CD8+ T cells were shown to be essential during the chronic stage of Mtb infection, as 
CD8-depleted mice had higher bacterial burdens (van Pinxteren et al., 2000; Mogues et al., 
2001). Mtb-specific CD8+ T cells were detected in the lungs and lung-draining lymph nodes 
of mice infected with Mtb, and these cells expressed perforin and were able to recognize and 
lyse Mtb-infected macrophages (Serbina et al., 2000). Moreover, challenging of CD8-depleted 
rhesus macaques with high dose Mtb led to loss of BCG vaccine-induced protection (Chen et 
al., 2009). Additionally, CD8+ T cells expressing granulysin, perforin and granzymes have 
been detected in granulomas of humans, macaques and cattle (Andersson et al., 2007; Diedrich 
et al., 2018; Palmer et al., 2019). Conversely, it has also been reported that Mtb-specific CD8+ 
T cells could be endowed with detrimental functions, as illustrated by the accumulation of IL-
10-secreting CD8+ T cells in mice that was associated with elevated susceptibility to Mtb 
infection (Cyktor et al., 2013). Moreover, expression of regulatory cytokines such as IL-10 and 
TGF- by CD8+ T cells was related to higher sputum bacterial load in individuals with 
pulmonary TB (Silva et al., 2014).  
 
In conclusion, our results add on to the growing body of evidence that shows the involvement 
of CD8+ T cells in TB immune responses. Our study limitations include small cohort size, we 
only investigated ESAT-6/CFP-10 responses, other Mtb antigen could be more immunogenic 
to induce CD8+ responses, and our samples were limited to studying peripheral blood. 
Additional studies with larger number of participants and focusing on the site of TB disease 









The only licensed TB vaccine (BCG) is protective against severe, childhood forms of the TB 
but is not effective against pulmonary TB, the most common form of the disease (Fine, 1995; 
Bo et al., 2008). Thus, the is an urgent need for a new and efficacious TB vaccine. Recently, 
there has been much excitement regarding a new promising TB vaccine candidate 
(M72/AS01E) that has been shown to provide 50% efficacy against pulmonary tuberculosis 
(Tait et al., 2019). Since there is a consensus regarding the critical role of Th1 cells in 
orchestrating an effective immune control against M. tuberculosis, Th1 cytokines (particularly 
IFN-) are the traditional measure of vaccine-induced immunogenicity (Soares et al., 2008; 
Norrby et al., 2017). However, IFN- secretion has proven to be a poor correlate of TB 
protection in BCG-vaccinated mice (Majlessi et al., 2006; Mittrücker et al., 2007).  
 
In this study, we sought to investigate immune responses to Mycobacterium tuberculosis (Mtb) 
beyond IFN- producing CD4+ T cells. We focused our analysis on a subset of CD4+ T cells 
named ‘Th22’ cells. We used healthy Mtb-exposed individuals to optimize IL-22 detection and 
investigate factors that influence Mtb-induced IL-22 production in whole blood and PBMC. 
Furthermore, we examined the impact of TB disease and HIV co-infection on Mtb-specific 
Th22 responses, in the context of better-characterized Th1 and Th17 responses. Blood samples 
from HIV-infected and uninfected individuals with Mtb exposure (latent TB infection) as well 
as TB disease were investigated, to assess the functional characteristics, memory, activation 





In Chapter 2, we showed that optimal detection of CD4+ IL-22 T cell responses was dependent 
on the type of assay and antigen formulations used for stimulation. Whole blood stimulation 
enabled robust detection of IL-22-producing CD4+ T cells, while IL-22 responses were poorly 
detectable in peripheral blood mononuclear cells (PBMC). We also observed that IL-22 
responses were induced by more complex antigens such as Mtb lysate, gamma irradiated Mtb 
whole cells and BCG, but not ESAT-6 and CFP-10 peptides. These data suggest that examining 
Th22 responses to Mtb may be hindered when only PBMC samples are available for study. 
Supplementing PBMC with soluble fractions from blood only partially restored IL-22 
responses. IL-22 responses in PBMCs were restored when labelled PBMC were added to 
autologous whole blood (Bunjun et al., submitted), indicating that IL-22-producing cells are 
indeed present in PBMC but lack physiological environment for optimal detection. Further 
studies could investigate whether cell subsets present in whole blood but not PBMC 
(neutrophils and possibly DCs) play a role in the production of IL-22 from CD4+ T cells, by 
depleting such cells in whole blood before stimulation or supplementing PBMC with them.  
 
Given that IL-22 induction was optimally detected following stimulation with complex Mtb 
antigen preparations, there was the possibility that it resulted from bystander activation from 
innate cytokines stimulated by pattern-associated molecular pattern molecules (PAMPs, such 
as mycobacterial cell wall constituents) stimulating pattern recognition receptors (PRRs, like 
Toll-like receptors) present in the antigen preparations. However, we determined that IL-22 
production was dependent on TCR signaling, and was not the result of bystander activation. 
Determining what antigen is recognized is important for inducing Th22 responses with a TB 
vaccine, in order to include that antigen in a vaccine; in this respect, whole cell vaccines may 




test different components and fractions of Mtb such  as cell wall, cell membrane, cytosol, lipids 
or lipoproteins (Seshadri et al., 2013), to determine if they induce IL-22 responses. 
 
IL-22 was mainly produced by CD4+ T cells that appear to be conventional, rather than 
unconventional MAIT,  or iNKT cells. In addition, IL-22 producing CD4+ T cells displayed 
a similar TCR V repertoire as IFN--producing CD4+ T cells. However, Mtb-specific Th22 
cells did display some unique phenotypic characteristics, namely differences in memory, 
activation and homing profiles compared to Th1 and Th17 cells. These data thus reveal 
interesting and novel features of IL-22-producing CD4+ T cells. Ongoing experiments in our 
laboratory aim to shed more light on the features of Th22 cells by isolating these cells using 
cytokine capture assays, and performing RNAseq to examine, among others, their lineage 
defining transcription factors, cytokine co-expression and receptor expression. 
 
Since its discovery in 2000, the role of IL-22 has been described in several diseases caused by 
bacteria, viruses, fungi, and parasitic infections (Dumoutier et al., 2000; Dudakov et al., 2015; 
Brias et al., 2016; Valeri and Raffatellu, 2016). IL-22 mainly acts of non-hematopoietic cells, 
to preserve mucosal barriers by promoting tissue proliferation, regeneration, and healing (Witte 
et al., 2010; Sonnenberg et al., 2011; Sabat et al., 2014). IL-22 also induces epithelial cells to 
produce antimicrobial peptides and proteins such as -defensins, the S100 family of peptides, 
Reg3, calprotectin and calgranulin A (Lin et al.,, 2017; Moyat et al., 2017; Tyler et al., 2017). 
Furthermore, IL-22 is involved in inducing chemokines from epithelial cells, which leads to 
recruitment of innate cells to the site of infection (Whittington et al., 2004; Aujla et al., 2008; 
Nograles et al., 2008). During infection with Citrobacter rodentium, an extracellular bacterium 
that infects the intestine, mice lacking IL-22 displayed more intestinal epithelial damage, 




critical against during lung infections in mice, where IL-22 neutralization aggravated 
dissemination of Klebsiella pneumoniae, but only in the absence of IL-17 (Aujla et al., 2008). 
Moreover, IL-22 deficient mice displayed severe lung injury and were impaired in the 
regeneration of tracheal epithelial cells during influenza infection (Kumar et al., 2013; Pociask 
et al., 2013). In the context of TB, IL-22 was reported to induce antimicrobial proteins, causing 
chemokine secretion (CCL2) that recruited macrophages to the site of disease (Treerat et al., 
2017). There is also possibly a direct effector function for IL-22, since IL-22 receptor has been 
detected on Mtb-infected macrophages, as well as macrophages in TB granulomas in humans 
and non-human primates (Dhiman et al., 2009; Zeng et al., 2011; Treerat et al., 2017). Indeed, 
IL-22 was shown to inhibit the growth of Mtb in mice by enhancing phagolysosomal fusion 
(Dhiman et al., 2009). Further studies are required to demonstrate whether IL-22 is indeed 
involved in protective TB immunity. These could include adoptive transfer of Th22 cells in 
mice, IL-22 neutralization in NHPs and examining vaccine-induced Th22 responses using 
current TB vaccine candidates in humans and NHPs. Longitudinal human studies involving 
LTBI individuals or household contact of TB patients could also be used to investigate Th22 
responses in individuals who progress to TB disease. A longitudinal study analyzing whole 
blood transcriptomic signatures in Mtb-infected adolescents reported on the low expression of 
Th17-associated genes IL-17F, IL-23R, RORC and CCR2 in individuals who progressed to TB 
(Chen et al., 2016; Scriba et al., 2017). Given that some of these genes are also associated with 
Th22 cells, further studies of Th22 cells are indeed warranted. 
 
IL-22 was reported to be essential for control of Mtb infection using the hyper-virulent clinical 
Mtb strain HN878 but dispensable when using laboratory adapted H37Rv and Erdman strains 
(Wilson et al., 2010; Khader et al., 2011; Behrends et al., 2013; Segueni et al., 2016; Treerat 




protection (Tsenova et al., 2007; Ordway et al., 2011). However, this observation is not 
consistent for all W-Beijing lineage strains (Bo et al., 2008). The high virulence of Mtb strain 
HN878 has also been shown to be associated with lower Th1 responses (Manca et al., 1999). 
Other studies propose that both Mtb and host genotype influence the disease outcome (Caws 
et al., 2008; van Crevel et al., 2009). It is important to determine whether a protective role for 
IL-22 is limited to infection with hyper-virulent Mtb strains. Further studies could investigate 
the role of IL-22 in TB during infection with clinal strains of Mtb that are not hypervirulent. 
 
Detrimental roles of IL-22 have also been reported, where uncontrolled expression caused 
tissue damage and chronic inflammation, leading to inflammatory skin diseases such as 
psoriasis through regulation of cellular differentiation, or development of several types of 
cancer by promoting the survival, proliferation and migration of cancerous cells (Wolk et al., 
2006; Schmechel et al., 2008; Akil et al., 2015; Lullo et al., 2015; Nardinocchi et al., 2015). 
Furthermore, induction of antimicrobial proteins by IL-22 was shown to favor Salmonella 
typhimurium colonization in the gut (Behnsen et al., 2014). Moreover, IL-22 contributes to 
Helicobacter pylori-associated gastritis by stimulating epithelial cells to secrete CXCL2, which 
leads to recruitment of myeloid-derived suppressor cells and inhibition Th1 cell responses 
(Zhuang et al., 2015). Further studies are required to determine which environmental, cellular, 
and molecular factors contribute to regulation and dysregulation of IL-22 production and 
function. Since IL-22 has been implicated in both pathogenic and protective roles (Sonnenberg 
et al., 2010; Zenewicz and Flavell, 2011), further studies are required to determine factors that 
could contribute to IL-22 having protective versus inflammatory pathogenic roles, including 
levels of IL-22 in the microenvironment, other cytokines present, IL-22 inhibitors (such as IL-





Extending previous work from our laboratory describing mycobacterial IL-22 responses 
(Bunjun et al., submitted), we detected substantial IL-22 production in response to stimulation 
with Mtb lysate, comparable to the IFN- response. Interestingly, Mtb-specific Th22 cells were 
reduced by 50% in TB patients. It is likely that Mtb replication could trigger recruitment of 
Th22 cells to the site of disease. Indeed, soluble IL-22 has been shown to be elevated at the 
site of disease during pulmonary as well as extra-pulmonary TB (Scriba et al., 2008; Matthews 
et al., 2011b). Furthermore, IL-22 producing cells have been detected in the lungs and 
granulomas of rhesus monkeys with TB (Qiu et al., 2008; Yao et al., 2010). The majority of 
IL-22 producing CD4+ T cells express CCR6, a chemokine receptor that binds chemokine 
ligand MIP-3,  mediating T cell homing to mucosal tissues during inflammation (Liao et al., 
1999; Acosta-Rodriguez et al., 2007; Bunjun et al., submitted). Interestingly, IL-22 
concentrations were increased in the blood after anti-TB treatment, indicating that the absence 
of Mtb replication may result in rehoming of Th22 cells to the circulation  (Zhang et al., 2014).  
If indeed IL-22 is a sensitive marker for clearance of Mtb at the site of infection, the 
recirculation of IL-22 to blood could potentially be a biomarker for monitoring treatment 
response. This could be tested using longitudinal studies involving TB patients receiving anti-
TB treatment, where IL-22 production from both the blood and the site of Mtb infection is 
measured throughout treatment.  
HIV infection is the greatest risk factor for TB mortality (WHO, 2019). The hallmark of HIV 
infection is the progressive decrease in CD4+ T cells which is associated with an increased risk 
of TB (Geldmacher et al., 2012). HIV is thought to preferentially infect and deplete Mtb-
specific CD4 T cells (Geldmacher et al., 2010), cause a decrease in polyfunctional CD4+ 
responses (Day et al., 2008) and alter the equilibrium of Mtb–specific CD4+ subsets (Riou et 
al., 2016). Studying HIV-induced defects in the immune response to TB could elucidate some 




effective TB vaccine. In this study, HIV infection resulted in reduced frequency and absolute 
Mtb-specific Th22 cells, especially in patients with TB. This is consistent with our recent 
findings (Bunjun et al., submitted). This is not surprising as Th22 cells are thought to be highly 
permissive to HIV based on expression of HIV co-receptors and integrin 47, and the lack of 
CCR5 ligands that induce autocrine protection against HIV infection (El Hed et al., 2010; Kim 
et al., 2012; Alvarez et al., 2013; Sivro et al., 2018). Preferential infection of Th22 cells can 
further be tested in longitudinal studies, by determining Th22 responses before HIV infection 
and at different time points after HIV infection. Other studies could infect Th22 cells with HIV 
in vitro or isolate Th22 cells from HIV-infected individuals/SIV-infected macaques to quantify 
integrated HIV DNA compared to other Th subsets in blood and tissues.  
 
In Chapter 4, we investigated Mtb peptide-specific CD4+ and CD8+ T cell responses in LTBI, 
active TB and HIV infection. Consistent with previous studies, we show that CD8+ T cells are 
able to produce Th1 cytokines (IFN- and TNF-), which have been shown to play an 
important role in effective control of Mtb infection (Rozot et al., 2013; Amelio et al., 2019). 
Again, consistent with published studies, these Mtb peptide-specific CD8+ responses were 
mostly detected in patients with TB, with fewer proportion in individuals with LTBI (Rozot et 
al., 2013; Amelio et al., 2019). We further report that HIV infection can impair memory 
differentiation of Mtb-specific CD8+ T cells, which could result in loss of CD8+ cytolytic 
activity (Appay et al., 2000; Andersson et al., 2007). Our results largely confirm data from 
previous studies and highlight the contribution of CD8+ T cells in TB immune responses. This 
compels the question of whether a TB vaccine will need to induce CD8+ responses to be 
protective against TB. Notably, several TB vaccines including BCG vaccine and candidate TB 
vaccines M72/AS01E, VPM1002 (rBCG), AERAS-402 have been shown to elicit robust CD8+ 




al., 2019).  Furthermore, CD8+ T cells were shown to be important in BCG vaccine-induced 
protection in rhesus macaques (Chen et al., 2009). Therefore, is it likely that an effective TB 
vaccine may need to induce CD8+ responses. 
 
This study had several limitations. We evaluated Mtb-specific responses in blood, and TB 
primarily affects the lungs. Therefore, it is important to determine whether the responses we 
detected in blood are consistent with those at the site of Mtb infection. Moreover, this was a 
cross-sectional study, and longitudinal studies investigating Mtb-specific responses in 
individuals who proceed to develop TB are warranted, to shed more light on Mtb immune 
responses. Future studies could also examine vaccine-induced Th22 cells as correlates of 
protection. Much remains to be determined regarding the role of Th22 cells in TB. Further 
studies are required to determine whether IL-22 is involved in direct killing of Mtb, or plays 
an indirect role in TB immunity; and conditions under which IL-22 may possibly play a 
protective or pathogenic role during Mtb infection.   
 
In conclusion, we confirm that Th22 cells contribute substantially to the CD4+ T cell response 
to Mtb. IL-22 appears to be produced by conventional CD4+ T cells but IL-22 induction may 
have specific antigen presentation requirements. Interestingly, HIV infection during TB 
disease led to a near absence of Th22 cells in blood, suggesting that increased risk of TB during 
HIV infection could be in part due to depleted Th22 cells. Our results warrant further study of 
the role of Th22 cells in TB immunity, which may lead to insights that could assist with the 
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Figure S1: The relationship between Mtb-specific CD4+ T cell activation with total CD4+ T cell 
activation profile. The relationship between total CD4+ T cells expressing HLA-DR with (A) IL-22 
producing CD4+ T cells and (B) IFN- producing CD4+ T cells expressing HLA-DR. Each dot represents 




 Figure S2: Comparison of the frequency of Mtb-specific CD4+ and CD8+ T cells in 
LTBI/HIV− (n=19), aTB/HIV- (n=18), LTBI/HIV+ (n=19), and aTB/HIV+ (n=15). (A) 
Representative flow cytometry plots showing IL-22 and IL-17 production by CD4+ and CD8+ T 
cells in response to stimulation with ESAT-6/CFP-10 peptide pool. Frequency of Mtb-specific 
CD4+ and CD8+ T cells producing (B) IL-22 and (C) IL-17 in four clinical groups. The bars 
represent the median. 
